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PREFACE
This thesis comprises an introductory review of the literature, followed by reports of two
experiments which are presented in the form of scientific papers. For this reason, there
may be some repetition between chapters, particularly in terms of experimental
procedure. To avoid unnecessary repetition, a single list of references is given at the
end of the thesis. For the sake of completeness , several appendices are attached to
Chapters Two and Three which would not ordinarily be included in a scientific paper.
The literature review looks at the passive transfer of immunity from the mare to the foal,
the consequences of failure of passive transfer of immunity and different methods of
testing whether the transfer of passive immunity has occurred. The review concludes
with a discussion of vaccination programmes against African horse sickness.
Trial One evaluated different tests for determining whether the transfer of passive
immunity from mare to foal has occurred in order to determine which of these tests
should be used preferentially. A single radial immunodiffusion test was used as the
reference standard. A series of samples .was taken from a group of foals and tested
using four methods: single radial immunodiffusion , glutaraldehyde coagulation, zinc
sulphate turbidity and protein refractometer tests.
Trial Two explored African horse sickness vaccination programmes, focusing on when to
vaccinate foals for the first time. A series of samples was taken from a group of foals
from birth until two months after their second set of African horse sickness vaccinations
(one year old). The samples were tested for the presence of African horse sickness
antibodies for each of the nine serotypes to determine when maternal immunity fades





Unlike cattle and sheep, which have been selected for reproduct ive efficiency for many
generations , horses are selected solely on performance characteristics; for example, .
movement for dressage, jump ing ability, racing ability and looks. This has made horse
breeding reproductively inefficient and makes the foals that are born all the more
valuable. It is therefore surprising that it was not until the 1980's that interest in equine
neonatology increased , and the contention that a weak foal is a dead foal , or worth no
more than a dead foal, was questioned (Koterba et al. , 1990). Equine neonatology can
be described in simple terms as intensive care of foals , but also includes methods of
early identification of problems and treatment to prevent the need for intensive care.
This includes the identification of cases where the transfer of passive immunity may be
problematic and the early identification of foals in which failure of passive transfer of
immunity (FPT) has occurred (Koterba et al. , 1990). Passive transfer of immunity is
defined as "a form of acquired immunity induced by the transfer of immune serum
containing specific antibodies or of sensitized lymphoid cells from an immune to a non-
immune recipient host" (Cruse & Lewis, 1995).
Jeffcott (1972) summarised the history of immunology as follows. Von Behring and
Ehrlich pioneered immunology in the early 1890's. In 1892, Ehrlich recognized the
important differences between active and passive immunity. Before 1900, colostrum was
considered either detrimental to the newly born foal, or to have beneficial purgative
qualities (Blaine, 1832). In 1900, Ransom indicated the importance of colostrum , when
he found that the first milk contains the most antibodies. The significance of this, in the
transfer of immunity, was only recognized in 1912 by Famulener. He showed that goats
have no antibodies in their serum at birth but that there is a rapid rise in serum antibody
levels after the ingestion of colostrum. He also showed that the absorption of antibodies
only occurs in the first few days of the goat's life. In 1922, Smith and Little further
demonstrated the importance of colostrum to the survival of the newborn. In an
experiment, they found that 75 to 80% of calves deprived of colostrum died, while all the
control calves, which received colostrum , survived.
In 1923, Kuttner and Ratner (cited in Jeffcott, 1972) suggested that there is a correlat ion
between placental structure and permeability to antibodies. This explained a number of
discrepancies in the early reports of placental permeability to antibodies. In 1938,
Schneider and Szathmary (cited in Jeffcott, 1972) described four groupings of animals,
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based on placental structure. They placed horses, pigs, cattle and goats in the first
group, which has no transfer of antibodies through the placenta. Of the three routes of
passive transfer of immunity (absorption by the endodermal cells of the yolk sac,
absorption through the placenta, and colostrum), the only one that operates in the horse
is postnatal transfer through the colostrum. This was confirmed by Ikeda (1924). Bardelli
(1930) Leme'tayer et al. (1946a, b) (all cited in Jeffcott, 1972). Mason et al. (1930)
found no detectable placental transmission of immunoglobulins in the mare.
The equine placenta is epitheliochorial (More/, 1993). This means that the placenta
consists of six cell layers - three on each of the maternal and foetal sides (Figure 1.1)
with an intervillous space between the foetal and maternal layers (Mullins, pers. comm.,
2006). This structure means that the mare's placental epithelium remains intact. The
allontois chorion lies against the mare's epithelium and villi and microvilli project into
crypts in the 'endometrium (Mullins, pers. comm., 2006). Although metabolite exchange
between the mare and foal circulations does occur, blood components. particularly large
molecules, such as maternal antibodies, are unable to pass through the equine placenta
(Morel, 1993). The foal therefore attains very little immunity, if any, in utero (Morel,
1993). The mare is able to give the newborn foal passive immunity, or a level of
temporary protection against common microorganisms which have challenged her
immune system, through the colostrum (Jeffcott, 1974a). Passive transfer of immunity
through the colostrum plays an important protective role against infectious diseases in
the foal (McGuire et al ., 1975; Clabough, 1990 cited in Brown et al., 1991 and Stoneham
et al. , 1991). Therefore colostrum containing low or borderline levels of immunoglobulin
G (lgG) poses a significant health risk to the foal (Zou et al. , 1998). The colostrum
supplies immunity from birth until the foal's own immune system is functioning at its
maximum capacity at an age of three to four months (Morel, 1993). Combined
immunodeficiency disease is a genetically inherited condition. Foals born with this
condition are unable to produce immunoglobulins of their own (Hayes, 1996). Foals with
combined immunodeficiency disease illustrate the protective effects of the maternal
antibodies quite clearly. The foals appear clinically normal for the first month, while
maternal antibodies are present, and then become highly susceptible to fatal infections










Figure 1.1 Figure showing the structure of the equine placenta. Note the six cell layers
(Morel, 1993).
1.2 Transfer of passive immunity
Active immunity is defined as the immunity resulting from the administration of an
antigen, Le. the antibodies are produced by the animal itself (Tizard, 2000), as opposed
to passive immunity which is defined as the immunity acquired by the transfer of pre-
formed antibodies (Davies, 1997). Passive transfer of immunity provides the foal with
temporary protection against microorganisms to which the mare has been exposed. In
horses, this protection is supplied through the colostrum. The mammary gland
selectively concentrates immunoglobulins from the blood (Figure 1.2). ImmunoglobulinG
(IgG) is present in the colostrum from the time that the colostrum is first available
(Pearson et al., 1984). The immunoglobulin levels in the milk of healthy mares are
insignificant by 24 hours post partum (Jeffcott, 1974a). The immunoglobulins are
absorbed by epithelial cells in the foal's small intestine. These cells are replaced by
mature epithelial cells within 38 hours (Jeffcott, 1973, cited in Jeffcott , 1974a). By 24
hours post partum, the new cells are unable to absorb the large immunoglobulin
molecules so it is important that the foal receives the colostrum early (Jeffcott, 1974a).
Immunoglobulins are absorbed by the epithelial cells of the small intestine, by
pinocytosis. Each cell absorbs as much as it can, before discharging the
immunoglobulins (and other molecules) into the intracellular space. The molecules pass
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In foal serum , IgG levels have reached a peak by 12 to 18 hours after the foal has
suckled for the first time. The lowest level is reached four to five weeks later , and the
levels then rise again to a second peak at six to eight months, remaining steady until the
end of the first year (Jeffcott, 1974b). In a trial by Jeffcott (1974b) , one group of foals
was allowed to suckle normally (Group 1), a second group was prevented from suckling
but fed supp lementary colostrum and hyperimmune serum (Group 2), and the third
group was deprived of colostrum and fed milk substitutes (Group 3). The pattern in IgG
levels for the first two groups was as described above and the only difference between
the groups was that the second group had higher levels of serum IgG. In contrast, the
third group had no serum IgG until the second week, followed by a steep rise until seven












Figure 1.4 Immunoglobul in G levels in colostrum-fed and colustrum-deprived foals
from birth to 1 year (Jeffcott, 1974b); Group 1 = normal suckling; Group 2
= no suckling and supplementary colostrum and hyperimmune serum ;
Group 3 =no colostrum.
1.3 Failure of passive immunity (FPT) and factors affecting passive
transfer of immunity.
The general definition of failure of passive transfer (FPT) is that FPT occurs when the
foal has inadequate blood levels of IgG (Brown et al., 1991). A more specific definition
of FPT is a blood count of less than 200 mg IgG per 100 ml serum. Partial failure of
passive transfer (PFPT) may be defined as less than 400 mg IgG per 100 ml serum
(McGuire et al., 1977; Rumbaugh et al., 1979 and Perryman &Crawford, 1979; Crawford
7
& Perryman, 1980 and Perryman, 1981 all cited in Pearson et al., 1984). In 1990, Leyet
al. wrote "the level of IgG transfer that is considered adequate is open to debate". Their
reasoning was that, although 400 mg per 100 ml serum was generally considered
adequate, high risk foals would benefit from higher levels of IgG. In addition the half-life
of maternal antibody is reported to be 21 to 24 days (Jeffcott , 1974a), so that a foal with
a 24 hr IgG level of 400 mg per 100 ml serum will have 200 mg IgG per 100 ml serum at
three weeks of age and a predisposition to humoral immunodeficiency at one month of
age until the foal's own immune system matures. Ley et al. (1990) suggested that more
than the immediate neonatal period of the foal needs to be considered when defining
FPT, as a foal with an initial IgG of 800 mg per 100 ml serum will be less predisposed to
developing infectious diseases at one to two months of age than foals with a lower initial
IgG level. More recently , the definit ion has been changed to less than 400 mg IgG per
100 ml serum for FPT and less than 800 mg IgG per 100 ml serum for PFPT (LeBlanc et
al., 1992; Wilkins & Dewan-Mix, 1994; Raidal, 1996 and Tyler-McGowan et al., 1997) .
Failure of passive transfer results in an increased likelihood of the foal developing
infectious diseases (McGuire et al. , 1977 and Clabough et al., 1991). Raidal (1996)
found a significant association between the foal's immune status and the incidence of
infectious disease. In contrast, no significant association was found between the
incidence of diarrhoea and the immune status of the foal. The reason for this is probably
that diarrhoea is usually associated with non-infectious causes.
1.3.1 Inadequate ingestion of colostrum
There are many factors that affect the occurrence of FPT. The most important of these
is inadequate ingestion of colostrum. Premature lactation by the mare is one of the most
common causes of FPT as the foal may not receive enough colostrum (Jeffcott, 1972;
Jeffcott, 1974a; Rumbaugh et al., 1979; Kruse-Elliot & Wagner, 1984 cited in LeBlanc et
al. , 1992; Varner & Vaala, 1986 cited in Lee et al., 1992 and Jeffcott , 1987 cited in Lee
et al., 1992). Possible reasons for premature lactation are placentitis, placental
separation or twinning (Jeffcott , 1974a).
If the IgG concentration in the colostrum is low, then FPT may still occur even if the foal
receives a large amount of colostrum (Jeffcott , 1972; Kruse-Elliot & Wagner, 1984 cited
in LeBlanc et al., 1992; Varner & Vaala, 1986 cited in Lee et al. , 1992 and Jeffcott, 1987
cited in Lee et al., 1992) .
The quantity of colostrum ingested and the time after birth that it is ingested are also
important. The quantity ingested affects the amount of IgG the foal will receive.
However, this is not a linear relationship as other factors including colostrum quality also
8
affect the IgG absorption (Jeffcott, 1972; Kruse-Elliot & Wagner, 1984 cited in LeBlanc et
al. , 1992; Varner & Vaala, 1986 cited in Lee et al. , 1992 and Jeffcott , 1987 cited in Lee
et al., 1992).
The time between birth and drinking the colostrum is important because the intestines
become impermeable to large molecules such as milk proteins and immunogloblins
(Jeffcott, 1972; Jeffcott, 1974a; Rumbaugh et al ., 1979; Varner & Vaala, 1986 cited in
Lee et al., 1992 and Jeffcott , 1987 cited in Lee et al., 1992). If the foal suckles late, then
FPT is likely to occur. Reasons for the foal suckling late include a foal that is born weak
(Jeffcott, 1972), with abnormalities (Varner & Vaala, 1986 cited in Lee et al., 1992 ;
Jeffcott, 1987 cited in Lee et al., 1992 and Raidal, 1996) or suffering from neonatal
maladjustment syndrome (NMS) (Varner &Vaala, 1986 and Jeffcott , 1987, both cited in
Lee et al., 1992). Neonatal maladjustment syndrome is a non-infectious, central nervous
system disorder of newborn foals that is associated with gross behavioural abnormalities
(Koterba et al ., 1990) .
Another important factor in FPT is gestation length. As gestation length falls below 335
days or exceeds 345 days, so colostrum and foal serum IgG concentrations decrease
(Clabough et al. , 1991 and Kruse-Elliot & Wagner , 1984 cited in LeBlanc et al., 1992) .
Longer gestation lengths may lead to low serum levels of IgG because of premature
closure of the foal's gastrointestinal tract to macromolecules . If gestation is short, low
serum levels may result because of inadequate amounts of IgG in the colostrum
(Clabough et al. , 1991 and Kruse-Elliot &Wagner , 1984 cited in LeBlanc et aI., 1992).
1.3.2 Other factors
A foal may receive a seemingly sufficient quantity of high quality colostrum and FPT may
still result. This would occur when the small intestine fails to absorb the
immunoglobulins (Varner & Vaala, 1986 and Jeffcott, 1987 both cited in Lee et al.,
1992). McGuire et al. (1975) suggested that failure to absorb ingested immunoglobulins
could be due to a factor in the mammary secretions affecting absorption , or an intrinsic
defect in the foal's absorption mechanisms. Another possible reason is stress at birth
(Morris, 1968 cited in Jeffcott, 1974a and Rumbaugh et al ., 1979). This may explain the
findings of Clabough et al . (1991) and Raidal (1996) that the type of delivery (normal or
assisted (dystocia)) affects the incidence of FPT.
The incidence of FPT is greater in premature or dysmature foals than in normal foals
(Jeffcott, 1974a; Rumbaugh et al ., 1979; Varner & Vaala, 1986 cited in Lee et al., 1992
and Jeffcott, 1987 cited in Lee et al. , 1992). A premature foal is a foal born at a
gestational age of younger than 320 days, which displays immature physical
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characteristics. A dysmature foal is a full term but immature foal that is usually
undersized (Koterba et al., 1990). The time in the season when the mare foals affects
the incidence of FPT (Clabough et al., 1991 and Raidal, 1996). A possible explanation
for this may be that serum IgG levels increase with total solar radiation (LeBlanc, 1990).
Mare age and parity also affect FPT (Clabough et al., 1991). LeBlanc et al. (1992) found
that FPT occurs more frequently in foals whose dams are greater than 15 years old.
Failure of passive transfer may be deliberately caused by human intervention when the
foal is not allowed to drink from the mare because isosensitization is possible (Varner &
Vaala, 1986 and Jeffcott, 1987 both cited in Lee et al., 1992). Isosensitization is a
condition similar to the rhesus negative condition in humans. The pregnant mare
becomes sensitized to the foetal red cell antigens inherited from the stallion and
produces antibodies, which are transmitted to the foal via the colostrum. Failure of
passive transfer is therefore a consequence of preventing the severe and often fatal
haemolytic anaemia through haemagglutination and haemolysis of erythrocytes (Jeffcott,
1974a).
Other less important factors in causing FPT have been identified. Very rarely, the mare
does not produce colostrum containing IgG (Jeffcott, 1974a). If the mare is clinically ill,
then FPT may occur (Varner & Vaala, 1986 and Jeffcott, 1987 both cited in Lee et al.,
1992). The sex of the foal may affect the transfer of passive immunity. Raidal (1996)
found that male foals have lower circulat ing IgG levels than females . Induction of
parturition may adversely affect the transfer of passive immunity but research is
inconclusive here (Townsend et al., 1983).
1.4 Testing for transfer of passive immunity
Testing for the transfer of passive immunity can be done on the mare's colostrum or the
foal's blood.
1.4.1 Testing co lostrum samples
One of the methods of testing for the transfer of passive immunity is to test the mare's
colostrum. The colostrum needs to be sampled soon after the foal suckles as the
protein levels in the colostrum fall steadily after suckling until negligible amounts are
reached between 18 and 24 hours later (Jeffcott, 1974b).
Pearson et al. (1984) recommended collecting colostrum within eight hours of parturition.
This allows the foal time to acquire passive transfer of immunity, but the colostrum has
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not yet been diluted by milk. These researchers suggested using single radial
immunodiffusion, to test the quality of the colostrum as described by Mancini et al.
(1965) and discussed further in Chapter 1.4.2.
LeBlanc et al. (1986) described an alternative method of testing the colostrum. The
colostral specific gravity was found to be a good indicator of foal serum levels , 24 hours
after parturition . The specific gravity of the colostrum is measured using a modified
hydrometer (Figure 1.5). The hydrometer consists of a specimen compartment with a
graduated scale (pycnometer) , in a water-filled column . The specific gravity is
determined by the depth at which the graduated scale of the pycnometer settles in the
water column. This instrument is known as a colostrometer and is calibrated so that
distilled water at 24°C has a specific gravity of 1.0 at room temperature (24°C). The
colostrum needs to cool before being tested , and on very hot or cold days the colostral
reading needs to be adjusted for an accurate measurement of the specific gravity . If the
colostral specific gravity is less than 1.06, the foal is more likely to have serum IgG
levels of less than 800 mg per 100 ml serum (FPT) than if the colostral specific gravity is
greater than 1.06 (Tyler-McGowan et al., 1997).
s p e c if i c 9 ra v i ty = 1 .0 6
d ist il led w a te r
Figure 1.5 Colostrometer used for determining the specific gravity of colostrum
(LeBlanc et al. , 1986).
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1,4.2 Testing blood samples
Although colostrum quality is an important factor in the development or prevention of
FPT, the involvement of other factors , such as the time between birth and first suckling,
the amount of colostrum that the foal drinks, failure to absorb immunoglobulins, etc.,
suggest that it may be better to test the foal directly. This would involve measuring the
blood serum levels of IgG (Clabough et al., 1991) .
Total serum protein (TSP) refractometry is a method of measuring the total protein in the
serum (McBeath et el. , 1971). This test uses the principle that the refractive index of a
solution is determined by its concentration . Proteins are the major components of blood
serum and so affect the concentration (McBeath et al., 1971), thereby affecting the
refractive index of the serum. A few drops of a serum sample are placed onto the face
of the prism and the serum protein scale read (Figure 1.6) (McBeath et al., 1971).
McBeath et al. (1971) found a positive correlation (r= 0.723, t > 0.1) between the




















Figure 1.6 Refractometer for measuring the total protein in serum. The inset shows
the serum protein scale on the left (McBeath et al., 1971).
Reid and Clifford (1974) found a positive correlation (r= 0.774, p < 0.001) between the
refractometer and another method of evaluation, the zinc sulphate turbidity (Z8T) test
(discussed below). Their conclusion was that, for lambs, the refractometer is an
effective although indirect method of measuring serum IgG. Reid and Martinez (1975)
found that, as the serum albumin levels of young calves and lambs are fairly constant,
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the refractometer gives an acceptable indication of the amount of globulin present in the
serum. They found that a refractometer reading of 7.0 or higher indicates successful
passive transfer of immunity . Rumbaugh et al. (1978) worked with mares and foals and
found a correlat ion of 0.58 between the refractometer and single radial immunodiffusion
(discussed below). However , the points were widely dispersed in relation to the line
(Figure 1.7). This means that serious errors could result if total protein values are used
to estimate the neonatal foal's IgG status. The measurement of total serum assumes
that a low total serum protein after suckling equates to a failure of passive transfer of
immunity , and further assumes that the serum protein concentration is constant from foal
to foal. Serum protein concentration varies greatly from foal to foal , and some foals
have a higher value pre-suckling than others have post-suckling. This overlapping of
values makes it difficult to interpret the TSP results and makes it an unreliable test
(Rumbaugh et al., 1978). LeBlanc (1990) evaluated the total serum protein or
refractometer test as follows : "Total protein is not useful in the foal for evaluating the IgG
level. Total protein varies greatly between individuals and is influenced by too many
factors to accurately estimate the IgG level."
The zinc sulphate turbidity (ZST) test is a simple and rapid method of testing serum IgG
levels. .The ZST test is a measure of the total serum immunoglobulin . It is based on the
format ion of a visible precipitate when immunoglobulin combines with zinc ions. Serum
(0.1 ml) is added to 6.0 ml of a ZnS04 solution (208 mg/I) (McEwan et al., 1970, cited in
Jeffcott , 1974a). Results can be estimated visually or with a spectrophotometer. Serum
IgG levels are estimated to be greater than 400 mg/100 ml serum when newsprint
cannot be read through the test tube. The advantages of this test are that it is
inexpensive and the results are available within an hour. A disadvantage is that there is
a high incidence of false positive results, possibly because of haemolysis in the serum
sample or unknown factors (non-spec ific precipitation) (LeBlanc , 1990). For this reason,
the test is best used as an initial screening test and a more dependable, but slower test,
used as verification (LeBlanc, 1990).
The latex agglutination test (LAT) is based on the observation of an agglutination
reaction when latex particles are mixed with serum or blood containing IgG. The
advantages of this method are that serum or whole blood can be used and the incidence
of false positives is much lower than with the ZST test (LeBlanc , 1990). However, the
test is affected by temperature and must be administered according to manufacturers
instructions (LeBlanc, 1990). This test is not readily available in South Africa.
The glutaraldehyde coagulat ion test involves the addition of 50 IJI of 10% glutaraldehyde
to 0.5 ml of serum. The serum is then observed for clotting (Beetson et al. , 1985 and
Ciabough et al., 1989). The clot is formed by cross-linking of the immunoglobulin
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Figure 1.7 Correlations of immunoglobulin concentration for neonatal foals measured
by radial immunodiffusion and estimated from total protein (refractometer
readings), (Rumbaugh et al ., 1978)
With the glutaraldehyde coagulation test, the results show an inverse correlation
between the time taken for coagulation and the amount of immunoglobulin present
(Figure 1.8) (Sandholm, 1974 and 1976). This test is highly specific and sensitive at the
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critical immunoglobulin values (400 and 800 mg/100 ml serum) . A positive coagulation
reaction is said to occur when a solid gel, which does not move when tilted, forms
(Figure 1.9). Negative reactions produce little or no change in the consistency of the
serum, or are soft gels that do not solidify within one hour of the addition of the
glutaraldehyde (Beetson et al. , 1985) . Failure of passive transfer is diagnosed if there is
no positive reaction after 60 minutes. Partial failure of passive transfer is diagnosed
when the positive reaction takes between 10 and 60 minutes. Normal transfer has
occurred if the positive reaction occurs within 10 minutes (Clabough et al., 1989) .
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Figure 1.8 Correlation of the log serum IgG concentration (gll) ~f samples giving a
positive glutaraldehyde coagulation test reaction (using a 10%
glutaraldehyde solut ion) and their coagulation time (minutes) (Beetson et
al ., 1985)
LeBlanc (1990) briefly described three other tests for blood serum. They are the
quantitative IgG test, the concentration immunoassay technology (CITE) test and the
radial immunodiffusion (SRID) test. The quantitative IgG test is a turbometric procedure
using automated chemistry equipment with anti-lgG . It is rapid and accurate but is
expensive and requires specialised chemistry equipment.
Workman (1987) described the concentration immunoassay technology (CITE) test as
an enzyme immunoassay. Two reactants (antigen and antibody) are brought together
with an enzyme attached to one component of the assay to measure the extent of the
reaction . A substrate or chromogen system is also available for the enzyme in order to
quantify the extent of the reactions. The sample is its own negative control because of
the test format. The CITE test is a rapid, foal-side (the test is performed almost
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immediately on the farm or in the veterinary clinic) semi-quantiative IgG test, producing
consistent and reliable results (Ley et al., 1990). LeBlanc's (1990) appraisal of the CITE







Example of glutaraldehyde coagulation results (own photograph).
The test that is regarded as the standard for IgG testing is the single radial
immunodiffusion (SRID) test (Ley et al., 1990). A single diffusion type of precipitate
reaction is performed by incorporating one reactant (usually antibody) into an agar gel at
a uniform concentration. The other reactant is introduced into a well from which it is
allowed to diffuse into the gel where it reacts with the internal reactant (Mancini et al.,
1965). Radial immunodiffusion is when the gel is spread on a surface with the diffusion
taking place radially starting from a circular well. These two methods in combination
form the SRID test (Mancini et al., 1965). The final area reached by the precipitate is
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directly proportional to the amount of antigen employed and is inversely proportional to
the antibody concentration, provided enough time is allowed for all the antigen to
combine. Temperature has no effect on the result (Mancini et al., 1965). The SRID test
as described by LeBLanc (1990) is accurate and allows specific quantitation of IgG.
This test can also be used on colostrum. The disadvantages of this test are that it is
expensive and the results are only available in 18 to 24 hours. Ley et al. (1990) used
the SRID as the comparison test when comparing other methods and stated that it is the
accepted standard for IgG tests .
1.5 The importance of testing for transfer of passive immunity
A foal is highly dependent on passive immunity for the first three to four weeks of its life.
The tests for the transfer of passive immunity concentrate on measuring the IgG
concentration because it has been shown that this is the immunoglobulin present in the
greatest amount in the colostrum and in the foal's blood serum (McGuire & Crawford,
1973). It is also the last immunoglobulin to reach the minimum level. Serum levels of
IgG reach a maximum level within 24 hours of the first drink and reach a minimum one to
two months after birth (McGuire & Crawford, 1973).
Brewer and Mair (1988), citing anecdotal reports, questioned the association between
low serum IgG levels and the subsequent development of illness that other researchers
had found. However they came to no conclusions themselves. Since this, Cohen
(1994) found that pneumonia is the major cause of death in foals of all ages and
septicaemia is the major cause of death in foals less than seven days old. He also
found that the assessment of passive immunity leads to decreased morbidity from
septicaemia and pneumonia. Raidal (1996) found that confirmation of the transfer of
passive immunity gives an important indication of whether a foal will have health
problems. Carter and Martens (1986; cited in Tyler-McGowan et al., 1997) found that
FPT is the most important contributory cause of disease in foals, especially septicaemia.
Tyler-McGowan et al. (1997) confirmed this. Cohen (1994), Raidal (1996) and Tyler-
McGowan et al. (1997) all agreed that the early recognition of FPT, by monitoring IgG
levels, is important for foal health.
1.6 Prevention and treatment of failure of passive transfer of immunity
For any disease condition, prevention surpasses treatment in efficacy. Colostrum is the
most important aid that vets and stud managers have in preventing FPT. There are a
number of precautions that can be taken to prevent FPT. The mare should arrive on the
farm where she is to foal at least a fortnight before foaling (Jeffcott, 1974a). The general
17
recommendation is that the mare be on the farm where she is to foal for six weeks
before foaling. This allows the mare time to produce immunoglobulins to local
microorganisms and for these to be included in the colostrum (Morel, 1993). Conditions
at parturition should be as hygienic as possible (Jeffcott, 1974a). The mare should be
attended at parturition, to prevent problems and to ensure that the foal suckles normally
and in good time. A colostrum bank should be kept on the stud farm if possible and care
must be taken with the collection, freezing and storage of the colostrum (Jeffcott,
1974a). Colostrum (180 to 250 ml) should be labelled, dated and moved to a freezer as
soon as possible (-15°C to -20°C). The colostrum should be quality-checked before
storage (Jeffcott, 1974a). If the colostrum is stored as described above, it must be used
within a year. If the colostrum is to be stored for more than a year it must be stored
below -25°C (Jeffcott, 1974a). LeBlanc (1990) stated that the foal should receive
adequate colostrum within the first six hours of life, while Koterba et al. (1990)
recommended that the newborn foal should be bottle fed if it has not had its first drink
within two to three hours of birth. These authors also suggested that the colostrum
quality and the foal's serum IgG level be checked.
Stoneham et al. (1991) recommended several management techniques to maximise the
foal's colostrum intake, in order to improve the transfer of passive immunity. When there
is a previous history of unexplained FPT, the foal should be given a minimum of 500 ml
donor colostrum orally, before it suckles its dam. When premature lactation occurs, at
least 550 ml of colostrum should be stripped from the mare and stored at. 20°C. When
the foal is born, the colostrum should be thawed in a warm water bath and given orally to
the foal before it suckles the dam.
The degree of mammary development in the mare and the colostrum should be visually
assessed. Jeffcott (1974a) described high quality colostrum as golden yellow, thick and
viscous. Stoneham et al . (1991) recommended that, if the dam's colostrum does not
meet this criterion, it should be supplemented with at least 550 ml of donor colostrum.
They further recommended the routine assessment of serum IgG levels between 12 and
72 hours after birth to identify foals at risk.
LeBlanc et al. (1992) recommended that the colostral specific gravity be measured as a
preventative method. A specific gravity of less than 1.06 would indicate that
supplemental colostrum should be given within 12 hours of birth. The recommendations
of Lee et al. (1992) support this. The foal may be slow to nurse but the changes in the
intestinal tract continue, so the time between birth and drinking must be monitored. If
the foal has not drunk within three hours, it should be assisted to drink or be fed
additional colostrum and then tested so that more colostrum can be given if necessary
(Lee et al., 1992).
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If FPT occurs, Jeffcott (1974a) suggested feeding the foal frozen or freshly collected
colostrum or administering the dam's plasma or an IgG preparation to it. The IgG
solution is subcutaneously administered and is not as effective as the dam's plasma
(Jeffcott, 1974a). The administration of the dam's plasma is not an option in cases
where the foal has been prevented from drinking the colostrum because the mare is
isosensitised to the foal. Stoneham et al. (1991) recommended a plasma transfusion, of
plasma with a minimum IgG of 15 g/1. The plasma donor should be the dam whenever
possible. If this is not possible, then compatibility tests need to be performed and the
donor should have been exposed to the same pathogens to which the foal will be
exposed (Stoneham et al. , 1991).
LeBlanc (1990) concurred with these recommendations but also mentioned the
disadvantages of the treatments . Oral IgG supplementation (colostrum or lyophilized
equine IgG) is the first treatment that is advised, because it is the natural route of
transfer of immunity and is the easiest treatment to administer. However, there is a time .
limit to its effectiveness and there is a limited availability of high-quality banked
colostrum . The other possible treatment is IgG supplementation by plasma transfusion.
This has serious disadvantages as a large volume of plasma is needed and the
administration of this volume of plasma may result in fluid overload when the foal's
circulation system is unable to cope with the extra fluid. Purchased plasma is expensive
and may not have the .protection required in the area of use. Plasma collection is time
consuming and advance planning is required to harvest plasma on the farm. An
alternative treatment of a purified IgG solution is recommended by Liu et al . (1991). The
advantage of this treatment is that it does not need to be administered as early as
colostrum. The amount that needs to be delivered intravenously is much less than when
administering plasma (200 to 300 ml vs 2 to 3 litres). The solution is prepared from a
large plasma pool and it therefore has a larger antibody spectrum and will supply better
protection than plasma from a single donor. Some adverse reactions have been
observed but these are no worse than reactions observed with the administration of
plasma (Liu et al ., 1991) .
The latest recommendations are those of Lee et al. (1992), which revert to the early
diagnosis of FPT, followed by colostral supplementation. If the diagnosis is later than 12
hours after birth, the intravenous administration of plasma is recommended .
Foals that are already clinically ill when FPT is diagnosed will require more plasma than
clinically healthy foals . III foals may require more IgG due to greater use of, or loss of,
IgG to pathologic processes. III foals should be rechecked at regular intervals in case
additional plasma therapy is required (Wilkins & Dewan-Mix, 1994).
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1.7 Passive immunity and vaccination programmes
The passive transfer of immun ity from mother to newborn is important in the well-being
of the newborn. However, it complicates vaccination programmes that are an integral
component of anima l husbandry at this time.
African horse sickness (AHS) is a disease endemic to South Africa and will be used as
an illustration of this problem . African horse sickness is a viral disease with nine
serotypes (Murphy et al. , 1999). It is an orbivirus of the reoviridae family and is the most
important and lethal virus of horses (Murphy et al., 1999) . It is an arthropod borne
disease, the most important vector being certa in species of the Culicoides biting midge
(Melior & Hamblin , 2004) . The disease is important financially, not only in the loss of
valuable horses but also in its effects on the export of horses : An effective control
programme is therefore essential. Factors that affect the incidence of the disease are
the number and concentrat ion of horses on the farm, movement of horses on to and off
the farm and external environmental and management influences (Wilson et al., 1995).
Although other factors are included in a contro l programme, including Culicoides control
practices, vaccination is an important part of disease control. The other factors in
disease prevention include surveillance, early detection , quarantine and hygiene
measures (Lunn & Townsend, 2000) .
Vaccination programmes should be tailored to each farm , taking into cons ideration the
age, type , number and use of horses , stocking density and value of the horses (Wilson
et al., 1995). Other factors that should be considered are the facilities , management,
geographic location and the potential exposure to the disease (Wilson et al., 1995). For
an effective vaccination programme to be developed, it is important to know when the
foals can first be vaccinated and how effective the vaccination is (Lunn & Townsend ,
2000) . Vaccination can only be considered effective when most of the animals in the
herd are immune . High herd immunity provides indirect protection of the susceptible
animals in the population (Lunn & Townsend, 2000) . Practically, the first and most
important immunisation for the foal is the transfer of passive immunity from the mare
(Lunn & Townsend, 2000).
Passive immunity gives immediate protection, through the transfer of pre-formed
antibodies , but is short-lived when compared to active immunity (Tizard , 2000) . Act ive
immunity does not result in immediate protection (Tizard, 2000) but it ensures that a
future encounter with the same antigen will trigger a faster and greater reaction than














Figure 1.10 The levels of serum antibody (degree of protection) conferred by active
and passive methods of immunisation (Tizard, 2000)
Vaccination may be passive or active. Here vaccination is taken to be active.
Vaccination is intended to provide an initial exposure to an antigen and most vaccination
... programmes require a booster to enhance the reaction (Tizard, 2000). This ensures that
if the antigen is encountered naturally, the reaction is fast and effective (Tizard, 2000).
The timing of vaccinations is important to ensure sufficient protection at all times. If a
vaccine is administered too late, there will be a gap in protection between the fading of
passive maternal immunity and the active protection from a vaccination. It is also
important that a vaccination is not given too early, as the maternal immunity may
negatively affect the active immune response (Tizard, 2000). According to Tizard
(2000), the requirements of a vaccine are that it induces a prolonged strong immunity in
both the animal and any foetus it may be carrying, produces no side effects, is cheap
and stable, with a reaction that is distinguishable from natural infection.
Aside from the requirements noted above, the four critical properties of a vaccine are as
follows (Ada, 1990; Tizard , 2000):
1) Stimulation of antigen-presenting cells so that the antigen is efficiently processed
and the appropriate cytokines are released.
2) Stimulation of 8 and T cells to generate large numbers of memory cells. Both
CD4 and CD8 T-cells are required so that both the MHC I and MHC IT complexes
can be reacted to (Lunn & Townsend, 2000).
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3) Helper and effector T cells generated for several epitopes , so that variation in
immune response is overcome.
4) Antigen persisting in lymphoid tissue, so that antibody-producing cells are
generated for long-lasting protection.
Most vaccination failures are the result of the vaccine lacking one of the four critical
properties above (Tizard, 2000). There are, however, other reasons for the failure of a
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Figure 1.11 Causes of vaccination failure (from Tizard, 2000)
The immune response development of the young animal is inhibited by the passive
immunity acquired from the mother (Tizard, 2000). The presence of immunoglobulins
from the mother prevents the successful vaccination of young animals by inhibiting
immunoglobulin synthesis (Figure 1.12) (Tizard, 2000). The amount of antibody
received from the mother and the half-life of the antibodies determine how long the
inhibition of the immune system will last (Tizard, 2000). The amount of antibody
transferred from the mother depends not only on her antibody level but also on how
efficiently antibodies were transferred to the newborn (Tizard, 2000).
The general recommendation for a vaccination programme is to vaccinate the mare two
to six weeks before foaling to maximise the colostral antibody concentrat ion and then to
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vaccinate the foals between six and nine months of age (Lunn & Townsend, 2000) .
However, although passively derived antibod ies have similar decay rates , studies on the
durat ion of maternal antibodie~ to different diseases indicate that the duration of the
protection varies (Liu et al., 1985). In addition, the decay rate of the antibodies is
dependent on the amount of IgG abso rbed by the foal (Liu et al., 1985). The foal's
antibody level is correlated to the antibody concentration in the mare 's serum and the
rate of decline is proportional to the initial antibody antibody titre (Alexander & Mason,
1941). If the mare is vaccinated or exposed to natural infection in the final two to six
weeks of gestation, then the colostral antibodies will be at a maximum (Lunn &
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Figure 1.12 The presence of maternal antibody in a newborn effectively delays the
onset of immunoglobulin synthesis through a negative feedback process
(Tizard , 2000).
It has been observed in the past few years that young foals, less than six months old,
have died of AHS (Gerdes and Mullins, 2002 , pers. comm.). This indicates that the
recommended AHS vaccination programme needs to be revised. When looking at two
of the nine AHS serotypes, Alexander and Mason (1941) found that colostral antibodies
are demonstrable for up to six months and that foals are refractory to vaccination for
even longer than this. These timings need to be reconsidered if foals are susceptible -to
AHS before six months of age, as concluded by Blackburn and Swanepoel (1988).
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These researchers found that maternally derived antibodies (from regularly immunised
mares) declined steadily over the five months the foals were tested from birth.
Antibodies to some of the serotypes were undetectable within two to four months of
birth. In addition, three foals vaccinated at three months and five foals vaccinated at four
months of age showed only weak responses to the vaccine , but the vaccination did not
adversely affect the existing immunity.
More research is needed to find the most effective time to vaccinate young foals against
AHS for the first time. The vaccination should be given before the maternal immunity
has faded but the maternal immunity needs to have faded sufficiently to allow an active
response. It appears from the research already completed that this time may be in the
period of three to five months of age.
1.8 Summary
The newborn foal is at risk from the development of infections as it adapts to its new
environment. The risk is decreased by the passive transfer of immunity from the mare
through colostrum. This immunity protects the foal until its own immune system is fully
functional.
Tests are available which enable the transfer of passive immunity to the foal to be
checked. The most effective tests are those that check the levels of immunoglobulin G
in the foal's blood. Alternatively the quality of colostrum can be checked, but some foals
ingest high quality colostrum and still experience failure of passive transfer (FPT) due to
other factors such as the time between birth and the first drink, the amount of colostrum
ingested and failure to absorb immunoglobulin , whilst others may not ingest the
colostrum.
If the foals are tested and the results are received quickly, failure of transfer can be
corrected by oral administration of colostrum or 19G. If the analyses take more than 24
hours, other treatment is necessary. Most commonly, this treatment consists of the
intravenous administration of plasma or a concentrated IgG solution. The testing for and
treatment of FPT results in fewer foals with infections and fewer deaths.
Passive immunity affects vaccination programmes, as the presence of maternal
antibodies inhibits the active immune response. This means that passive immunity
affects the timing of the first vaccination in two ways. The vaccination will only be
effective when the passive immunity has faded sufficiently to allow an active response,
but the vaccination should not be given after the passive immunity has declined to non-
protective levels. A complication is that different antibodies have different half-life times
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and so the most effective time for the first vaccination varies for different diseases. A
disease such as AHS is even more complicated in that the antibodies to the different
serotypes break down at different rates.
The objective of this literature review was to give the background of, and the link
between the subject matter covered in the two experiments that are discussed in the
next two chapters. The final chapter consists of the overall conclusions that can be
drawn from the trial results. The first experiment looked at the different tests for
determining whether the transfer of passive immunity from the mare to the foal has
occurred, and which of these tests should be used preferentially . The second
experiment looked at African horse sickness vaccination programmes focusing on when
to vaccinate foals for the first time.
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CHAPTER 2
TESTING FOR IMMUNOGLOBULIN IN NEONATAL FOALS
LJI Crow", DE Mullins2 and GD Bradford"
2.1 Abstract
The results from four locally available tests for the transfer of passive immunity from the
mare to the foal were compared to the results of the single radial immunodiffusion
(SRID) test for immunoglobulinG (lgG). The SRID test yields quantitative estimates of
IgG status (mg/dl serum) and is regarded as the benchmark or standard test in
assessing transfer of immunity. Failure of passive transfer of immunity (FPT) is indicated
at <400 mg/dl IgG, while partial failure (PFPT) may be indicated at IgG values
<800mg/dl. Fifty foals born in 1999 on the Camargue stud in the KwaZulu-Natal
Midlands were used in this trial. Samples of the colostrum, mare's blood and umbilical
blood were taken at foaling. Repeat samples of the foal's blood were taken in the
morning and afternoon following the birth of the foal and a final sample was taken the
following morning. The colostrum was tested for specific dens ity using a colostrometer
and the blood samples were tested using the refractometer, zinc sulphate turbid ity
(ZST), glutaraldehyde coagulation (GC) and SRID tests for IgG.
There were significant correlations in the values for IgG status between the three
inexpensive tests and the SRID test (colostrum, p=0.1; refractometer, GC and ZST,
p=0.01). The ZST and GC tests express IgG status in categories, relative to the critical
IgG levels of 400 and 800 mg IgG/dl serum. The refractometer yields a quantitative test
result, allowing regression analysis to be used to give a prediction of the SRID result
from refractometer readings. This analysis suggests that refractometer readings of 6.30
and 6.58 equate to SRID readings of 400 and 800 mg/dl, respectively. Chi-squared
analysis of the GC, ZST and refractometer results showed there to be a significant
relationship (p=0.1) between observed and expected IgG values for all three tests . Over-
and under-estimation of IgG status (% samples , compared to the SRID test results) were
found to be, respectively, 7.04 and 2.82 (GC) , 11.97 and 4.93 (ZST) and 12.68 and 0.7
(refractometer).
1 University of KwaZulu-Natal , Private Bag X01, Scottsville , 3209
2 Mooi River Veterinary Clinic , p.a. Box 9, Mooi River, 3300
r
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Although the SRID test gives the most accurate measure of IgG status in the foal, the
other tests are inexpensive and provide a diagnosis within one hour (refractometer and
ZST within 10 minutes, GC within 10 minutes if positive, longer if negative). This trial
showed the results of three tests (refractometer , GC and ZST) to be strongly correlated
with those of the SRID test. The choice of which test to use is therefore one based on
cost and ease of use. The colostrum test is not a sufficiently reliable predictor of transfer
of immunity from mare to foal.
The recommendation for the best time to take the sample from the foal remains at six
hours of age or soon thereafter. The age of the mare, her parity and the gestation length
did not have an effect on the transfer of passive immunity in this trial.
2.2 Introduction
Transfer of passive immunity is a very important factor in the health of the newborn foal.
Tests are available to assess whether failure of passive transfer has occurred and
treatments are available if failure is suspected. There is a need to determine which of
the locally available foal-side (on the stud or in the veterinary clinic) tests - zinc sulphate
turbidity, glutaraldehyde coagulation , protein refractometer and colostral specific density
- provides the most accurate diagnosis of failure of passive transfer (FPT): If there is no
difference in accuracy between methods, the simplest or cheapest test can be used. In
addition, if the best time to take the foal's blood sample for testing can be determined
then repeat samples and testing can be reduced and the foals that require treatment can
be treated as quickly as possible.
The age of the mare, her parity (Clabough et al., 1991) and the gestation length (Kruse-
Elliot & Wagner, 1984, cited in LeBlanc et al., 1992; Clabough et al. , 1991) have been
reported to affect the transfer of immunity from the mare to foal. These three factors
were also investigated in this trial.
The protein refractometer and colostral specific density test results are quantitative while
the zinc sulphate turbidity and glutaraldehyde coagulation test results are categorical -
either positive, partially positive or negative. The single radial immunodiffusion (SRID)
test is assumed to be the most accurate means of evaluating the IgG status on a
quantitative basis and is used as the benchmark test in this work.
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2.3 Materials and methods
The trial was conducted on all the foals born to 50 mares during September and October
1999 on the Camargue stud farm in the KwaZulu-Natal Midlands.
The following samples were taken for each foal : mare's colostrum (100 ml into plastic
tubes); mare's blood (10 ml into red-top (no additive) Vacutainer' test tubes (by jugular
venipuncture with 20 G needles), within 30 minutes of the foal being born) ; foal's blood
at birth (10 ml into red-top (no additive) Vacutainer test tubes (from umbilicus)); and
three further samples from the foal in the following 36 hours (juqular venipuncture, 20 G
needles, 10 ml into red-top (no additive) Vacutainer test tubes) .
The blood samples were centrifuged (at room temperature, 4000 rpm) on arrival at the
Mooi River Veterinary Laboratory (half-an-hour to several hours after sampling), for ten
minutes or until the serum was liquid (some serum became gel-like during centr ifuging).
The serum was then poured into 5 ml plastic mailing tubes. The refractometer, ZST, and
GC tests were performed immediately after the serum was separated, while the
remaining serum was frozen (-5°C) in the mailing tubes, until the SRIO test could be
performed.
The colostrum was tested for specific density using a colostrometer (LeBlanc et aI.,
1986). The blood samples from both mare and foal were tested for the presence of
immunoglobulin G using four tests . The tests used were: protein refractometer
(McBeath et al., 1971) ; zinc sulphate turbidity (ZST; LeBlanc, 1990); glutaraldehyde
coagulation (GC; Beetson et al., 1985) and single radial immunodiffusion (SRIO; Mancini
et al. , 1965). The SRIO test used was a commercially available kit from VMR04 . The
SRIO test is regarded as the standard or benchmark test for IgG (Ley et al. , 1990). The
technique of SRIO is the most widely used method for quantitative determination of
classes of immunoglobulins and other serum and plasma proteins. This techn ique
combines rapid and easy sample application with a high degree of accuracy and
reproducibility. Antiserum specific for the prote in to be measured is incorporated into
agarose gel. The sample antigen diffuses into the gel containing the antibody, and a
ring of precipitation forms that is proportional in size to the concentration of the antigen .
A linear relationship exists between the diameter of the ring and the concentration of the
antigen when plotted on semi-log graph paper. This method is time and temperature
dependent (SRlO information and instruction sheet from VMRO (Append ix 1) and
Mancini et aI., 1965)
3 BD Vacutainer Systems, Preanalytical Systems, Bellliver Ind. Estate , Plymouth , PL6 lBP, UK.
4 VMRD Inc, PO Box 502, PUllman, WA, 99163 , USA
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The refractometer" is calibrated using distilled water. Sufficient water to cover the
screen over the prism face (Figure 2.1) is placed on the screen using a 1 ml syringe, the
cover plate is lowered into place and the gauge is set to zero. The screen is then dried





Figure 2.1 The parts of a refractometer for measuring total serum protein. The inset
shows the protein scale on the left (McBeath et al., 1971). .
The ZST test is performed using 0.1 ml of serum and 5 ml of zinc sulphate" solution (208
mgll). The zinc sulphate is measured into test tubes and the serum is added. A
precipitate forms. If newsprint can be read through the test tube, then the result is
negative, Le. failure of passive transfer of immunity from mare to foal has occurred and
the foal has an IgG status of less than 400 mgldl of serum. If newsprint cannot be read
then the result is positive, Le. passive transfer of immunity from mare to foal has
occurred and the foal has an IgG status of more than 400 mgldl.
For the glutaraldehyde coagulation test, 0.3 ml of serum is added to 0.01 ml of 10%
glutaraldehyde. The test tube is checked after 10 minutes and again after an hour. If
the resulting gel is solid within 10 minutes, the result is positive Le. passive transfer of
5 Manufactured by Atago, Japan. Available from Polychem Supplies, p.a. Box 17254, Congella, 4013.
6 Merck Chemicals (Pty) Ltd, Laboratory Supplies Division. p.a. Box 2805, Durban, 4000. Product
code/Description: SAAR758286aEM, Zinc Sulphate unIVAR, Analysis Grade
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immunity has occurred and the foal has an IgG status of more than 800 mg/dl. If the gel
is solid between 10 minutes and an hour, the result is a weak positive Le. partial failure
of passive transfer has occurred and the foal has an IgG status of between 400 and 800
mg/dl. If there is no gel after an hour, the result is negative Le. failure of passive transfer
of immunity has occurred and the foal has an IgG status of less then 400 mg/dl.
The manufacturers instructions were followed for the SRID test (Appendix 1). Briefly, 3 1-11
of the standards (supplied) and the samples are added to the wells. The plates are
covered and left at room temperature for 18 to 24 hours. The diameters of the standards
are then read (in mm) and a standard curve developed. The diameters of the samples
are then compared to the standard curve.
Minimums, maximums, means, standard errors and standard deviations were calculated
for the SRID 12 hour, colostrums , SRID all sample, GC, ZST and refractometer results.
Correlations were then calculated between the different testing methods. Linear
regression was used to obtain a prediction of SRID values from the refractometer
values. The chi-square analysis was used to test the association between the SRID test
and each of the other tests. . Finally analysis of variance was used to test whether the
age of the mare, parity of the mare or gestation length had an effect on the IgG status of
the foal at 12 hours of age.
2.4 Results
The full test results are shown in Appendix 2. The summarised, descriptive statistical
results for each of the tests are shown in Table 2.1 .
Table 2.1: Summary of descriptive statistics for tests for IgG status in newborn foals
Test No Missing Min Max Mean SE Std Deviation
SRIDa 12 hours 50 0 89 5442 2101 168.2 1190
Colostrum 47 3 1 1.1 1.07 0 0.024
SRID (All samples) 142 0 31 5969 2082 101 .6 1210.8
GCb 142 0 1.0d 3 2.8 0.04 0.48
ZSTc 142 0 1.0d 3 2.78 0.04 0.51
Refractometer 142 0 5.4 9.4 7.41 0.08 0.9
a SRID = Single radial immunodiffusion test (mg/dl)
C ZST= Zinc sulphate turbidity test
b GC= Glutaraldehyde coagulation test
d 1.0 = negative; 2 = weak positive; 3 = positive
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Correlations were used as the first test to determine if there were differences in
sensitivity and accuracy between the different testing methods. The ZST, GC and
refractometer tests showed a positive, significant correlation with the SRID test at the
0.1% level of significance. The colostrum:SRID correlation was positively significant
only at the 1% level. Given this difference and the large variation in the colostrum
results it was decided not to proceed with further analysis of the colostrum results . Table
2.2 shows the correlation table for the three tests that warranted further analysis.
Table 2.2: Correlation values for the IgG tests (p = 0.01)
Test SRID GC ZST Refractometer
SRIDa 1
GCb 0.484 1
ZSr: 0.432 0.57 1
Refractometer 0.776 0.679 0.517 1
a SRID =Single radial immunodiffusion test
C ZST = Zinc sulphate turbidity test
b GC = Glutaraldehyde coagulation test
Linear regression analysis was used to obtain a prediction of SRID values from the
refractometer value , in order to determine refractometer values for the critical values of
400 and 800 mg/dl (the determining points for a positive, weak positive or negative IgG
result) for a chi-squared analysis. For the ZST and GC tests, which are categorical in
nature, results are stated in terms of these critical values, Le. positive (>800 mg/dl) ,
weak positive (400 - 800 mg/dl) and negative «400 mg/dl), so no further manipulation of
the data was necessary. The regression analysis was performed using Genstat 4.21
(2000) . A small number of high leverage values were eliminated from the data set. The
eliminated values were the last nine values when the data were sorted in ascending
order on SRID value . The eliminated SRID values ranged from 4125 to 5970 mg/dl. This
was done on the basis that the range of the refractometer is limited and that these nine
SRID values were outside of this range . The eliminated values were all high SRID
values . The resulting distribution graph is shown in figure 2.2. The resulting equation
was:
IgGRefractometer = 6.023 + 0.0006957 * IgGsR1D(r'value = 60.5%, SE = 0.540)
The critical refractometer values are therefore 6.30 and 6.58 for 400 and 800 mg/dl
respectively. Practically, since the refractometer is measured in intervals of 0.2, this
would equate to readings of less than 6.2 or 6.4 for an IgG level of less than 400 mg/dl
(as 6.3 falls directly in the middle of these two values). The implications of choosing the
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relevant cut off level (6.2 or 6.4) are covered in the Discussion below. A value of 6.6 or
greater would be equal to 800 mg/dl IgG or greater. The values in between would be the
values for a weak positive result (400 to 800 mg/dl).
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Figure 2.2 Fitted and observed relationship between the refractometer readings and
SRID IgG value.
The chi-square analysis, here, is a test of the association between the SRID test and the
other test in question (ZST, refractometer or GC). A significant chi-square result means
that the null hypothesis of no association between the readings is untrue. The chi-square
analysis was used as a result of a problem with the experimental design. The blood
samples were only tested once with each diagnostic test. This meant that, although
there were multiple samples from each foal, there were no replications. The lack of
replications meant that the regression for the prediction of a SRID result from the
refractometer was not as accurate as it could have been. In addition, it limited the
choice of statistical tests that could be used.
The chi-square analysis (n=142) (see Table 2.3 for calculations) showed a value of 130
for the GC test followed by 78 for the refractometer and 32 for the ZST tests (using
refractometer readings of 6.4 and 6.6 for 400 and 800 mg/dl IgG, respectively). These
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results were all significant (p=0.1), indicating a strong association between the results of
the SRID test and each of the other tests.
The GC test over-estimated the successful transfer of immunity (7.04% false positives),
while the ZST and refractometer tests produced 11.97 and 12.68% false positives,
respectively (Figure 2.2). The number of false negatives recorded were 2.82, 4.93 and
0.7% for the GC, ZST and refractometer, respectively (Figure 2.3).
If 6.2 and 6.6 had been used as the refractometer readings for 400 and 800 mg/dl IgG,
respectively, the false negatives would have been 11.97% and the false positives 1.40%.
If less than 7 had been used as a negative result (Reid &Martinez, 1975), instead of 6.6,
the false negatives would have been 18.8% and the false positives 0.70%.
Zinc SUlphate Turbidity Glutaraldehyde Coagulation
[i!] OVer 0 Under 1\1 8:lual
Refractometer
Figure 2.3 Graphic representation of false positives and negatives when compared
to SRID results.
Analysis of variance was used to determine whether the followinq three factors: age of
the mare, parity of the mare and gestation length had an effect on the IgG status of the
foal at 12 hours of age. The Genstat, 2000, generalised analysis of variance (for
unbalanced treatment structure) was used as the factors were non-orthogonal to each
other. None of the main effects (age of mare, parity of mare, gestation length) were
significant at the 1% level of significance. Since the factors were non-orthogonal, it was
not possible to test interactions between the factors. See Appendix 3 for the analysis of
variance tables.
Table 2.3: Chi-square calculations between single radial immunodiffusion (SRID) and other tests for immunoglobulin G.
Glutaraldehyde coagulation I Zinc sulphate turbidity I Refractometer
Observed
SRID 1 2 3 Totals 1 2 3 Totals <6.4 6.4-6 .6 >6.6 Totals
<400 4 1 0 5 1 2 2 5 6 0 0 6
400-800 0 8 3 11 2 6 3 11 6 ' 3 1 10
>800 1 9 116 126 3 12 111 126 8 4 114 126
Totals 5 18 119 142 6 20 116 142 20 7 115 142
Expected
<400 0 1 4 0 1 4 1 0 5
400-800 0 1 9 0 2 9 1 0 8
>800 4 16 106 5 18 103 18 6 102
(Obs - Exp)2 lexp
<400 83 0 4 3 2 1 31 0 5
400-800 0 31 4 5 13 4 15 13 6
>800 3 3 1 1 2 1 5 1 1




Although there has been much research into the transfer of passive immunity in foals,
there is very little data on the IgG levels of the mares. The VMRD information sheet for
the SRID test cites values for Shetland ponies from the work of McGuire and Crawford in
1972. The mean IgG of 20 animals sampled in this work was 1334 ± 350 mg/dl serum.
The mean value for the 50 Thoroughbred mares in the trial reported here was 2092 ±
660 mg/dl serum. The full summary statistics by age group are shown in Table 2.4.
Table 2.4 : Summary statistics for Thoroughbred mares IgG levels (mg/dl)
Age Number of samples Mean Minimum Maximum
5 3 1870 1361 2369
6 5 2019 1425 2369
7 5 1707 1031 2160
8 1 1492 1492 1492
9 3 2082 1579 2507
10 4 1908 940 2369
11 10 2386 1361 3938
12 6 2042 1637 2262
13 3 1966 1773 2062
14 3 2497 1637 3591
15 5 2324 1299 3591
16 1 1563 1563 1563
20 1 2369 2369 2369
2.5 Discussion
The results from the trial reported here suggest that the foal should be tested between
six and twelve hours of age. The earliest that there was a positive SRID result was for a
sample taken 4.5 hours after birth. The other three tests all showed this sample as a
negative (ZST and refractometer) or weak positive result (GC). A sample taken 6.25
hours after birth was the first that had a positive result from all four of the tests. There
were several false positives after this time from the ZST, refractometer and GC tests.
Given the results above, the choice of which test to use for testing foals for the transfer
of passive immunity will depend on the relative costs, availability and ease of use. The
colostrum specific density is an indirect test of the foals IgG status. This tests the
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colostral specific gravity and there are many factors other than the colostrum that affect
the success or failure of the transfer of passive immunity. The colostrum test is not a
sufficiently reliable predictor of transfer of immunity from mare to foal as no predictive
point for failure of passive transfer could be determined from results in this trial. The
other three tests are very similar to each other in cost, ease of use and the time taken to
obtain a result. The refractometer gives a result that does not need interpretation and
should be independent of the person performing the test, but it also gave the most false
positive results, although it returned very few false negatives. The zinc sulphate turbidity
test is open to different interpretation of results by different technicians, the number of
false positive results was high and this test returned the most false negative results. The
glutaraldehyde coagulation test result does not require any interpretation and returned
the least number of false positive results.
A false positive result when testing the foal's IgG status is potentially more serious than
a false negative. If the result is a false negative, the foal may be treated unnecessarily,
while, if the result is a false positive, the foal requiring treatment will be missed and will
not be treated.
Seventeen of the 50 foals in this trial were treated for failure of passive transfer of
immunity having been diagnosed with a serum IgG level of less than 800 mg/dl at
approximately 12 hours of age by anyone of the three simple laboratory tests (ZST, GC
or refractometer). An IgG of less than 800 mg/dl was assumed for refractometer
readings of less than 7.0 (Reid & Martinez, 1975). Despite the results of the three
simple tests, the SRID test showed that only six of these 17 foals had, in fact, suffered
FPT7 or PFPT8. Treatment was therefore unnecessarily administered to 11 foals. The
treatment of choice on this stud was serum transfusions from the mare, on other farms
colostrum or other more expensive treatments may be unnecessarily used in cases of
false negatives.
Of the six foals that were diagnosed as FPT at 12 hours, only one attained a consistent
level of IgG above 800 mg/dl after treatment, and this was reached at the test taken 56
hours after birth. This foal was accurately diagnosed as PFPT by the GC test at 12
hours, and inaccurately diagnosed as FPT by the ZST test and as positive by the
refractometer test at 12 hours. At 56 hours, it was inaccurately diagnosed as PFPT by
the ZST test.
One of the six foals diagnosed as FPT at 12 hours after birth never attained a blood IgG
status of 400 mg/dl according to the SRID test even after treatment. The results for this
7 FPT = Failure of pass ive transfer of immunity « 400 mg IgG/dl serum )
8 PFPT = Partial failure of passive transfer of immunity (400 - 800 mg IgG/dl serum)
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foal are shown in Table 2.5. The refractometer and GC tests correctly diagnosed this
foal with FPT while the ZST test incorrectly identified a PFPT for the first sample and a






Immunoglobulin G results for foal that remained below 400 mg/dl.
Refractometer ZSTc GCb (mg/dl) SRIOa (mg/dl)
5.4 Weak positive . < 400 89.99
5.4 Positive < 400 313.38
5.4 Positive < 400 285.72
a SRID =Single radial immunodiffusion test
C ZST =Zinc sulphate turbidity test
b GC =Glutaraldehyde coagulation test
The remaining four foals diagnosed as FPT by the SRIO test, all reached a blood IgG
level of between 400 and 800mg/dl before approximately 30 hours after birth (according
to the SRIO test) and after treatment. Of these foals, three were correctly diagnosed at
12 hours by all three tests as having PFPT and the last was correctly diagnosed by one
test as FPT (ZST) and incorrectly by two tests as PFPT (refractometer and GC). The
improvement in the blood serum IgG level of these foals was correctly identified by an
increased refractometer reading. The GC test correctly identified an increase to
between 400 and 800 mg/dl in two of the foals and incorrectly identified the other two
foals as having an IgG level of >800mg/dl. The ZST test did not identify the
improvement in one foal and incorrectly identified the other three results as > 800 mg/dl.
None of the foals requiring treatment were missed in this trial as the results of three tests
were used and foals were treated if anyone test showed less than full transfer of
passive immunity. If only the refractometer had been used, five of the foals needing
treatment would have been treated if a value of 7.0 was used as the 800 mg/dl reading.
Only five of the foals would have been treated if either the GC or ZST tests had been
used Le. each test would have missed one foal (a different foal for each test!). Both the
foals that were identified as having suffered FPT were identified by the refractometer as
the readings were 5.4 and 6.0. Of the four foals identified PFPT, two would have been
identified as FPT if either 6.2 or 6.4 had been used as the refractometer reading for FPT.
One would have been identified as PFPT with 6.6 as the refractometer reading for PFPT
and either 6.2 or 6.4 as the lower reading. The last foal had a refractometer reading of
7, so was not identified as PFPT using a cut- off level of less than 6.6 or7.0.
All of these tests are easy to use. The costs involved would be that of the refractometer
and colostrometer, and of the reactants for the other two tests. Other costs such as the
test tubes and syringes are constant between the tests.
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The results of this trial agree with the conclusions of Clabough et al. (1991) that it is
better to test the blood directly, rather than testing the colostrum for IgG. This is
because of the involvement of other factors affecting the absorpt ion of the IgG. These
factors include the time between birth and the first drink, the amount of colostrum
ingested and failure to absorb immunoglobulin , whilst other foals may not ingest the
colostrum. These factors mean that, although the colostrum is of a good quality and
contains sufficient IgG, the foal may still suffer failure of passive transfer of immunity.
Regarding the refractometer test, Reid and Martinez (1975) found that a refractometer
reading of greater than 7.0 meant that calves and lambs had successful transfer of
passive immunity. This is a higher reading than the values 6.4 or 6.6 reported in this
trial. Rumbaugh et al. (1978) found a correlation of 0.58 between the SRID and the
refractometer results, which is lower than the correlation of 0.776 found in this trial.
These researchers (Rumbaugh et al., 1978) found that the points were spread a long
way from the regression line, indicating that false positive and false negative results
were likely. Figure 2.2 (in results section) shows the distribution of the refractometer
values from the trial reported here, while Figure 2.4 shows the data of Rumbaugh et al.
(1978).
In a summary of the available tests for transfer of passive immunity, LeBlanc (1990)
stated that the disadvantage of the zinc sulphate test is the number of false positive
results. This problem was also evident in this trial with a high number of false positive
results (17 foals , 11.97%). In addition, false negative results (7 foals , 4.93%) were also
recorded in this trial.
The glutaraldehyde coagulation test was described by Beetson et al. (1985) as highly
specific and sensitive at the critical IgG values of 400 and 800 mg/100 ml serum. This
was confirmed in this trial as the GC test gave the lowest number of false positive results
(10 foals, 7.04%) and second lowest number of false negative results (4 foals, 2.82).
There was no significant effect of age of the mare, parity of the mare and the gestation
length on the IgG level that the foals attained, as tested using the SRID test on the
sample taken as closely aspossible to 12 hours of age. See ANOVA results (Appendix
3). These factors might have had an effect on the time that the foal achieved the 800
mg/dl level of immunity but this was not tested in this trial. Other researchers have found
that the age of the mare (LeBlanc et al., 1992), parity of the mare (Clabough et al., 1991)
and the gestation length (Clabough et al ., 1991 and Kruse-Elliot &Wagner, 1984 cited in
LeBlanc et al., 1992) have an affect on the transfer of passive immunity from the mare to
the foal. FPT was most prevalent in mares greater than 15 years old (LeBlanc et al. ,
1992). Mares which have had more foals were more likely to have foals with FPT
(Clabough et al., 1991), and primiparous were no more likely to have FPT than
multiparous mares (Clabough et al., 1991). The highest mean IgG concentration was in
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foals born between 335 and 345 days of gestation and decreased either side of these
values (LeBlanc et al., 1992). No effect was found in this trial, but only one foal was born
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Figure 2.4 Correlations of immunoglobulin concentrations for neonatal foals measured
by radial immunodiffusion and estimated from total protein (refractometer
readings) (Rumbaugh et al., 1978)
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The SRID test, which is a quantitative one, would be the ideal test to use if it were not for
the length of the assay and the need for a prompt result. The foal-side test needs to be
completed before the foal is 18 hours old in order that colostrum supplementation can be
given before absorpt ion of the IgG can no longer take place from the intestine. If other
treatments are preferred , they still need to be administered as soon as possible for the
foal's protection. The SRID test takes 18 hours to complete . The assay length for this
test cannot be decreased since the accuracy of the test decreases as there is no longer
sufficient time for the antibody-antigen complex to develop. This test can still be used as
a confirmation test for use after a foal has been treated or for foals that continually test
negative when the other tests are used. As an example, there was a foal in the trial
reported here that did not have a positive result for any sample from any of the simple
tests, but the SRID test results were positive for all of the samples. The SRID test
should also be used occasionally to test the accuracy of the other tests under different
laboratory conditions and with different technicians .
A more recently developed test than the ones covered in this trial is the SNAP Foal IgG
test from IDEXX. Pusterla et al. (2002) compared this test with the SRID test and found
it to be quick and easy to use. They found an overall agreement of 64% between the
two tests , with the greatest agreement being for the high (>800 mg/dl; 97%) and low
«200 mg/dl ; .93%) IgG levels. They concluded that the test would provide an adequate
assessment of the passive immune status of the foal and allow treatment of any deficient
foal early.
In conclusion, the specific density of colostrum was shown not to be a good predictor of
the transfer of passive immunity. The colostrum specific density test should still be used
to test the colostrum that is going to be stored for use in treating failure of passive
transfer. The choice of the ZST, GC or refractometer tests as the foal-s ide test will have
to be decided on by the stud manager and veterinarian, taking into account local
conditions. The SNAP test may also be an option. The current recommendations of
testing the foal six hours after birth and treating before 18 hours of age with colostrum
remain . The age of the mare, parity of the mare and the gestation length did not appear
to affect the transfer of immunity from the mare to the foal.
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CHAPTER 3
OPTIMUM TIME FOR VACCINATION OF FOALS AGAINST AFRICAN HORSE
SICKNESS
LJI Crow9, DE Mullins" and T Cerdes"
3.1 Abstract
An investigation into the duration of the maternally derived antibodies for African horse
sickness (AHS) in foals and the effect of the age of the foal at first vaccination on the
reaction to the vaccinat ion was undertaken.
Twenty-four foals, born on the Camargue stud in the KwaZulu-Natal Midlands in 2000
were used in this trial. The mares were all vaccinated on the same day, regardless of
their expected foaling date. The foals were all vaccinated with the initial and booster
vaccinations on two set days, regardless of the age of the foal when these vaccinations
were given. Blood samples were taken from the mare at foaling; from the umbilical cord
and from the foal at approximately twelve hours of age. Repeat samples were taken .
from the foals at monthly intervals until two months after the second set of vaccinations.
These samples were tested with a virus neutralisation test to determine the antibody
titres for each of the nine AHS serotypes.
The antibody titres for the nine serotypes of African horse sickness varied between the
mares and within the mares. The immunity that the foal received from the mare (in
terms of all nine serotypes) also varied between foals and within the foals. The maternal
immunity faded to a negative antibody titre for all serotypes in all the foals by 18 weeks
of age (mean = 4.44 ± 4.99 weeks; median = 4 weeks) . In the majority of foals, the
maternal immunity persisted for less than eight weeks. The number of serotypes that
the mare carries positive antibody titres for appears to affect the maternal immunity that
the foal receives from the mare. Although maternal immunity may interfere with the
foal's response to the AHS vaccination , the data reported here provide worrying
evidence that many foals are unprotected by either maternal immunity or vaccination for
periods up to 16 weeks .
9 University of KwaZulu-Natal , Private Bag, X01, Scottsville , 3209
10 Mooi River Veterinary Clinic , P.O. Box 9, Mooi River, 3300
11 Virology Department, Onderstepoort Veterinary Institute , Private Bag X5, Onderstepoort , 0110
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Results showed that successful reaction to the vaccine is affected by the age of the foal
at the first vaccination , the anti-AHS titre of the foal on the day of vaccination, and the
time between the mare vaccination and the birth of the foal (all of which are correlated) .
There was a wide variation in response to all nine serotypes between the foals and
within the foals. Positive antibody titres were most numerous to Serotype 1. Foals born
at either end of the foaling season enjoyed poorer protection against AHS than those
born in the middle of the season. Early season foals received poor levels of maternal
immunity but responded well to the first vaccinat ion; whereas late season foals enjoyed
more lasting maternal immunity which interfered with their response to the AHS
vaccination and left them susceptible to the disease after vaccination. A case study of
three foals is used to illustrate the differences in reaction in foals born at different times
during the season (different lengths of time between mare vaccination and foal birth and
different foal ages when vaccinated for the first time) .
Fewer foals responded to the second vaccination than to the first but the response was
faster indicating that the foals may have been building on a memory response from the
first vaccination.
The pattern of response to vaccination observed in this trial is in large part due to the
common management practice of vaccinating all mares on a farm on a single day,
regardless of expected foal ing date; and of vaccinating all foals on a single date,
regardless of exact foal age. A recommendation is made that management practices
need to change in order to adhere more closely to the recommended vaccination
schedule. It is suggested that the existing vaccination schedule be revised as follows:
the mare should be vaccinated at three and two months prior to her expected foaling
date with AHS 1 and AHS 2 respectively; and the foal then vaccinated at four and five
months of age with AHS 1 and AHS 2 and again at six (AHS 1) and seven months of
age (AHS 2). This revised vaccination schedule seeks to address the lack of immunity
present in many foals before the first vaccination , due to low levels of maternal immunity,
and to improve the efficacy of the booster vaccination. The mares are vaccinated at the
optimum time to improve the passive immunity given to the foals and the foals are
vaccinated as early as possible , with respect to the disappearance of maternal immunity.
3.2 Introduction
Vaccination programmes are an integral part of animal husbandry . in order to minimise
the risk of infection and the incidence of infectious diseases. Maternal immunity derives
from immunoglobulins concentrated by the mammary gland from the blood and passed
to the foal through the colostrum. Maternal immunity protects the foal but also affects
vaccination programmes (Jeffcott, 1974).
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Immunoglobulin synthesis in the young animal may be inhibited by the presence of
antibodies from the mare, thus preventing a successful vaccination reaction if the foal is
vaccinated at too young an age (Tizard, 2000). However, it is equally important that the
foal is vaccinated as early as possible so that there is no period of time when the foal is
not protected.
Liu et al. (1985) found African horse sickness virus (AHSV) maternal antibodies present
until foals are approximately seven months old. However, Blackburn and Swanepoel
(1998) found that antibodies to some serotypes disappear by two to four months after
birth. Field observations seem to confirm that Afr ican horse sickness (AHS) antibodies
reach very low levels in foals before six months of age (Gerdes and Mullins, 1999, pers.
comm.) .
African horse sickness is a severe, non-contag ious, viral equine disease with mortality
rates of up to 95% (Murphy et al., 1999) but there is minimal available field data on the
foal's immune response to the AHS vaccine. For an effective vaccinat ion programme to
be designed , data are needed on the duration of maternal immunity , and the variability in
this duration. Data are also needed on the efficacy of repeated vaccinations , taking into
account the age at which the animal is first vaccinated .
The African horse sickness vaccination 12 is a freeze dried, polyvalent vaccine containing
live attenuated virus strains and is split into two vaccines. The animals are initially
injected with the first vaccine (AHS 1) and then three weeks later with the second
vaccine (AHS 2) of the combination. The first vaccine contains Serotypes 1, 3 and 4.
The second vaccine contains Serotypes 2, 6, 7 and 8. Serotypes 5 and 9 are not
included in the vaccine. There is some cross protection between the following serotype
pairs: 1 and 2, 3 and 7, 5 and 8 and 6 and 9 (Coetzer & Erasmus, 1994). The
vaccination package insert states that foals born to unvaccinated mares can be
inoculated at any time but foals born to vaccinated mares should not be vaccinated until
they are at least six to seven months of age. All animals should be vaccinated in early
summer and mares should not be vaccinated in the first three months of pregnancy.
Annual immunization is recommended. The insert further states that immunity starts to
develop two to three weeks after complete inoculation , that protect ion to some serotypes .
is achieved after four weeks and that immunity cannot be guaranteed in all animals. The
complete package insert is given in Appendix 4. The recommended vaccination
programme is that foals born to susceptible mares are vaccinated at one month of age
and foals from immune mares in high risk areas are vaccinated at five to six months of
age and again in spring (August to September; approximately 12 months of age). The
recommended vaccination programme for adult animals is annually , in spring, except for
12 Onderstepoort Biological Products, Private Bag X07, Onderstepoort 0110, Registration No. G116 (Act 36 of
1947).
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pregnant mares, which should be vaccinated six weeks before foaling (Onderstepoort
Biological Products , 2005). This recommended programme is illustrated in Figure 3.1.
6 weeksMare Vaccinat ion
AHS1
3 weeks Mare Vaccinat ion
AHS2 --~_. _- - - -
Foal
born




3 weeks Foal Vacci nat ion About 6 months




3 weeks Foal Vaccinat ion
AHS2 .
Figure 3.1 Time line for the recommended vaccination schedule for pregnant mares
and foals.
Different serotypes may be active during an outbreak but usually one serotype will
dominate an outbreak , with a different dominant serotype the next season (Coetzer &
Erasmus, 1994). It has never been reported that an animal has been infected by more
than one serotype (Howell, 1968 cited in Coetzer & Erasmus, 1994). The infections may
occasionally spread into provinces that are usually free of AHS, causing serious losses.
The south-western Cape Province is the quarantine zone for export horses. Prior to
1990, the last outbreak in this area was in 1967 (Erasmus, 1990 cited in Coetzer &
Erasmus, 1994).
The South African horse industry is a multimillion rand industry in a niche market. The
figures from the latest outbreak of African horse sickness (January to Apr il 2005) are as
follows:
KwaZulu-Natal : 535 cases and 361 mortalities (including a yearling worth R550 000);
Mortalities in other provinces: Gauteng 42; Eastern Cape 33; Limpopo 2; North West:
3; Mpumalanga 2; Western Cape 2.
Total: 445 mortalities.
These figures represent reported cases and are likely to underestimate the severity of
the outbreak , since many cases are not reported from the rural areas. The serotypes
that were circulating in January to April 2005 outbreak were Serotype 1 (Gauteng,
Limpopo), Serotype 2 (Eastern Cape), Serotype 5 (KwaZulu-Natal - mainly in the Natal
Midlands, Gauteng and Western Cape - suspected introduction from KwaZulu-Natal),
Serotype 6 (Gauteng) and Serotype 7 (KwaZulu-Natal - mainly in the Dundee district);
(Gerstenberg, 2005, pers. comm.).
Results from samples submitted to the Onderstepoort Veterinary Institute for testing
between 1981 and 2004 show that Serotypes 3, 5 and 9 are seldom found. Serotype 9
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originates from North Africa and has only recently (1993) been isolated for the first time
in South Africa (Gerdes, 2004, pers. comm.). Two isolates of AHS Serotype 9 were
found in five years (1993 to 1998) and there have been fourteen isolates in the last six
years (1999 to 2004). The prevalence of the nine serotypes is illustrated in Figure 3.2.
The endemic zones of AHS are currently restricted sub-Saharan Africa and possibly
Yemen (Melior & Hamblin, 2004). But, the virus has a history of rapid expansion without
warning into countries far beyond these endemic areas and climate changes have
resulted in the major vector (Culicoides imicola) expanding into many areas of Europe
previously considered AHS risk free (Melior & Hamblin, 2004). The related bluetongue
virus which is transmitted by the same Culicoides vector has already moved into this
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Figure 3.2 Occurrences of different serotypes of African horse sickness in South
Africa between 1981 and 2004 (Gerdes, 2005, pers. comm.)
The objectives of this trial were to determine when, after parturition, the maternal
immunity to AHSV has decreased to a sufficiently low enough level to allow the first
vaccinations for AHS to be given to the foals, and to determine the effect of repeated
vaccinations on AHSV antibody levels in young horses, taking into account the age at
which they were first vaccinated. Other factors which affect AHSV antibody levels in
foals and which were studied in this work are the mare's antibody level on the day of
foaling and the time period between the mare being vaccinated and the foal being born.
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3.3 Materials and methods
All the foals born on the Camargue stud farm in the KwaZulu-Natal Midlands in 2000
were sampled at birth, 12 to 24 hours after birth and monthly thereafter until two months
after their second set of AHS vaccinations , at approximately one year old. Each set of
vaccinations consisted of both halves of the combination (AHS 1 and AHS 2). A sample
of blood was taken aseptically by jugular venipuncture (20 G needles into 7 ml red-top
(no additive) Vacutainer" test tubes) from the mare within 30 minutes of foaling. Blood
was collected from the umbilicus at birth as the foal's zero-hour sample.
The blood samples were allowed to stand before being centrifuged. The serum was
decanted into 5 ml plastic mailing tubes 14 and frozen until the analyses were performed.
The 12 hr samples were tested for the transmission of passive immunity from the mare
to foal by testing the immunoglobulinG (lgG) status using the glutaraldehyde coagulation
(GC) .(Beetson et al., 1985) and ·zinc sulphate turbidity (ZST) (LeBlanc, 1990) tests
before being frozen (Appendix 6).
Initially, 61 foals were sampled at birth, but a complete set of samples was collected on
only 24 foals . Foals were excluded from the trial for the following reasons: a negative
IgG status.(according to either GC or ZST test); death (mainly due to physical injuries);
missing samples (foals not brought in from the field , too small a sample taken or other
management reasons) or because the mare and foal were moved to another stud farm
during the trial period. Two foals (numbers 20 and 21) that tested negative for IgG
status were included in the trial in error. Only 24 of the remaining foals were tested with
the virus neutralisation test due to time and funding constra ints. The foals were all born
between August and November 2000 and all were vaccinated on the same day, so their
ages ranged from three to six months at the time of the first vaccinat ion and from 12 to
15 months at completion of sampling. This vaccination schedule does not comply with
the Onderstepoort Biological Products (OBP) recommendations (Figure 3.1, above) in so
much that the mares were vaccinated from 4.5 weeks to 19.5 weeks before foaling and
the foals were vaccinated for the first time from nine weeks to 24 weeks of age. The
foals were then vaccinated six months later as per the OBP recommendations. This
type of schedule represents standard practice on stud farms in the KwaZulu-Natal
Midlands (Mullins, 2005, pers. comm.).
The 24 complete serum sample sets were tested in the Onderstepoort Veterinary
Institute virology laboratories using the virus neutralisation test (Appendix 5) for the
presence of sero-specific antibodies for each of the nine AHS serotypes .
13 BD Vacutainer Systems , Preanalytical Systems, Bellliver Ind. Estate, Plymouth , PL6 7BP, UK.
14 Mailing tubes with polyethylene screw-on caps, AEC Amersham, (Pty) Ltd, P.0 . Box 1596, Kelvin 2054.
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The virus neutralisation test is performed using a constant amount of virus against
dilutions of serum and the criterion for positive antibody by microscopic reading is the
complete neutralisation of the virus input, Le. the absence of viral cytopathic effect (CPE)
(Anderson & Rowe, 1982). Thus, the virus neutralisation test is a quantitative assay for
the determination of antibody titre in, for example, serum, based on the ability of the
serum to neutralise a known amount of a standard virus antigen (Aleff Group, 2000).
Neutralisation tests estimate the ability of antibody to neutralise the biological activity of
antigen, when mixed with it in vitro. Viruses may be prevented from infecting cells after
a specific antibody has combined with and blocked their critical attachment sites. This
reaction is the basis of neutralisation tests that can be used for the identification of
unknown viruses or the measurement of specific antiviral antibody (Tizard, 2000).
Neutralisation tests are highly specific and sensitive (Tizard, 2000). The African horse
sickness virus neutralisation test is a sero-specifictest that measures the amount of IgG
and IgM antibody specific to each serotype in the serum. The test uses decreasing
concentrations of the serum against a set amount of virus to determine how much
neutralising antibody is present in the serum. The test result is read in antibody titres
doubling in strength from 1:2 to 1:4 to 1:8, increasing to 1:256. An antibody titre of 1:40
is considered to indicate a positive result (Onderstepoort Veterinary Institute, 1995). The
layout of the analysis in this work meant that the results measured were either side of
1:40 (1:32 and 1:64); 1:32 will be considered the lowest positive reading for the rest of
this discussion.
3.4 Results and discussion
For the purposes of this discussion, Vaccination 1 and 2 refer to when the first and
second sets of the vaccine were administered, not the individual vaccines (AHS 1 and
AHS 2) within the combination. When an individual vaccine within the combination is
referred to, AHS 1 and 2 will be the terminology used. AHS 1 refers to the combination
of Serotypes 1, 3 and 4; AHS 2 refers to the combination of Serotypes 2, 6, 7 and 8.
3.4.1 Duration of maternal immunity
Figure 3.3 shows the mares' antibody titres for each serotype on the day of foaling. It
can be seen that there is a large variation in antibody titres both between mares and
within mares for the different serotypes.
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Only one mare had a negative titre for Serotype 6 and two mares had a negative
antibody titre for Serotype 1, while 8 had negative antibody titres for Serotype 3 and 14
had negative antibody titres for Serotype 2. The antibody titres for Serotypes 5 and 9
would result from the cross reactions with Serotypes 8 and 6 respectively ,' or from
natural exposure. The antibodies from vaccine reactions and those from natural
exposure are not differentiated in the test.
Mare 10 had antibody titres at each of the measured levels (1 :2 to 1:256). Serotypes 1,
2, 3, 6 and 9 had negative antibody titres and the rest were positive . In contrast the
range of antibody titres for Mare 2 was all positive from 1:32 to 1:256.
Figure 3.4 shows the variation in the immunity that the foal received from the mare as
determined when the foal was approximately twelve hours old. The variat ion between
foals and within one foal between serotypes is clearly illustrated. There are fewer foals
shown in this figure than mares shown in Figure 3.3 because there was not sufficient
serum for all the foals to test for all the serotypes for this set of samples .
Factors which may affect the maternal immunity that the foal receives are the age of the
mare and the number of serotypes that she is positive for. Figure 3.5 shows the mare
age against the number of serotypes that the foal had positive results for at four to six
weeks of age. There is no clear pattern of response but, if the number of serotypes that
the mare had a positive test result for on the day of foaling is compared to the number of
serotypes that the foal is positive for at four to six weeks of age (Figure 3.6), then a
clearer pattern is visible . The more serotypes that the mare is positive for, the more
serotypes the foal is positive for.
Table 3.1 shows the duration of the maternal immunity (weeks) for each of the
serotypes. The mean and median values show that the majority of the foals have
maternal immunity that lasts less than eight weeks. The overall mean (all foals, all
serotypes) is 4.44 ± 4.99 weeks. The median is 4 weeks. Only 11 .1% of the foals had a
maternal immunity (all serotypes) that lasted for eight weeks or longer. Figure 3.7
illustrates the variation in the duration of the passive immunity received from the mare
and that the immunity is not long lasting. Across all serotypes, maternal immunity did
not extend beyond 18 weeks after foaling . These data (Figure 3.7) include four foals
that still had a positive antibody titre at the time of the vaccination. Therefore , in these
cases, the maternal immunity may have lasted until after vaccination and possibly
beyond 18 weeks , although this is unlikely.
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Figure 3.3 Mare antibody titres for AHS serotypes (1 to 9) on the day of foaling (Serotype: 1 +, 2 SI, 3 A , 4 X, 5 *, 6 e, 7 +, 8 - , 9 - )
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Figure 3.4 Antibody titres for foals at twelve hours of age for each of the nine African horse sickness serotypes
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Figure 3.5 The effect of the mare's age on the number of serotypes that the foal is
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Figure 3.6 The effect of the number of serotypes that the mare is positive for at
foaling on the number of serotypes that the foal is positive for at four to six
weeks of age.
The difference between the maternal antibodies and those produced by the foal in
response to vaccination cannot be determined in these four foals. If these foals are
removed from the data set (Table 3.1, highlighted in green) then the pattern of the
degradation of maternal immunity remains the same (Table 3.2, Figure 3.8). Of the four
foals that still had a positive antibody titre on the day that they were vaccinated for the
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first time, two of these foals had a positive antibody titre for more than one serotype
(Serotypes 1, 4 and 6; and Serotypes 1 and 6). These antibody titres were recorded on
the day that the foals were vaccinated with the vaccine combinat ion (AHS 1 or AH8 2)
containing the relevant serotype. The serotypes highlighted in purple for Foal 5 are
those for which this foal had negative antibody titres from birth, with sudden, unexpected
positive antibody titres on the day of the vaccination. The duration of maternal immunity
for these serotypes, in this foal, has been taken as zero weeks as it is not known
whether the antibody titres on vaccination day are a testing error or genuine antibody
titres resulting from natural exposure to these serotypes.
Table 3.1: Duration of maternal immunity (weeks)
Foal 81 82 S3 84 85 86 S7 S8 S9
1 0 0 4 4 0 0 0
2 10 0 10 4 4 10
3 4 0 8 4 8 8 8 4 4
4 8 4 0 4 8 10 8 10 8
5 - 0 12 06 10 10 10 4 10 12 10 4 12
7 10 0 0 6 8 12 0 10 8
8 6 0 0 0 8 8 0 8 16
9 0 0 4 0 8 12 8 0 4
10 0 0 0 1t 4 0 0 8 8
11 4 0 0 0 8 0 0 0 0
12 4 0 4 14 4 0 12 4
13 14 4 4 4 0 8 8 8 8
14 0 0 0 0 0 4 0 12 0
15 6 0 6 0 12 18 6 16 18
16 6 0 0 0 6 12 0 0 4
17 0 16 0 0 16 8 6 8 6
18 6 0 0 0 12 6 0 16 6
19 12 4 0 12 12 4 4 12 18
20 6 0 0 0 6 6 0 0 0
21 0 0 0 6 0 0 0 0 0
22 0 0 0 0 0 6 0 6 6
23 0 0 0 0 0 0 0 0 0
24 0 0 0 0 0 12 0 0 0
Mean 5.17 2.17 1.33 3.00 6.92 7.25 2.58 5.75 5.83
Std dev 4.82 4.21 2.87 4.13 4.97 5.03 3.61 5.48 5.75




Mean and median duration of maternal immunity when foals that had
positive antibody titres on the day of vaccination are removed from the
data set.
Serotype 1 Serotype 4 Serotype 6
Mean 4.38 2.18 6.82
se 4.54 3.14 5.04
Median 4.00 0.00 7
Table 3.3 shows the anti-AHS antibody titre of each foal, for each of the seven serotypes
included in the vaccinations, on the day that the foal was vaccinated for the first time
(light blue cells represent the positive antibody titres). As can be seen from the limited
colour in Table 3.3, very few of the foals still had a positive level of maternal immunity
when vaccinated. The oldest foal with a positive antibody titre when vaccinated was 108
days old (14 weeks) . These results do not agree with the findings of Alexander and
Mason (1941) who found that passive immunity to African horse sickness lasts for
approximately 6 months, but confirm the findings of Blackburn and Swanepoel (1998)
and field observations (Gerdes and Mullins , 2000, pers . comm.) that maternal, immun ity
fades before the foals are six months old. In addition , it implies that the foals could be
vaccinated earlier than six months of age without maternal immun ity compromising the
react ion to the vaccine. If the foals were vaccinated at 120 days (four months) for the
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Figure 3.7 Duration of maternal passive immunity in foals for each of the nine African horse sickness serotypes (all 24 foals) as



































Figure 3.8 Duration of maternal passive immunity in foals for each of the nine African horse sickness serotypes (four foals positive at
vaccination removed) as measured by positive virus neutralisation antibody titres
(Serotypes: 1 +,2 D, 3 , 4 5 *, 6 e, 7 +, 8 - , 9 - )
~
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Table 3.3: Foal antibody titres for the African horse sickness virus serotypes in the
vaccine on the day of the first vaccination (Vaccination 1) with the relevant
vaccine combination (AHS 1 or AHS 2)
Foal No. Age at 1st
1 2 3 6 7 8
1:2 1:2 1:21 65 1:2
2 69 1:16 1:8 1:8 1:4
3 74 1:4 1:4 1:2 1:8 1:8 1:4
4 83 1:4 1:2 1:8 1:2 1:2 1:8
5 86 1:2 1:2 1:2 1:2
6 91 1:8 1:8 1:8 1:4 1:16 1:16 1:2
7 96 1:16 1:2 1:2 1:2 1:8 1:2 1:8
8 99 1:8 1:4 1:4 1:4 1:8 1:2 1:4
9 105 1:4 1:2 1:2 1:2 1:16 1:2 1:2
10 106 1:2 1:2 1:2 1:2 1:2 1:8
11 108 1:2 1:2 1:2 1:2 1:4 1:2 1:2
12 108 1:2 1:2 1:4 1:2 1:2 1:8
13 122 1:16 1:2 1:4 1:4 1:8 1:2 1:2
14 128 1:2 1:4 1:2 1:2 1:2 1:2 1:8
15 130 1:8 1:4 1:2 1:2 1:16 1:2 1:4
16 131 1:8 1:2 1:2 1:2 1:16 1:2 1:4
17 134 1:4 1:2 1:2 1:4 1:4 1:4 1:4
18 139 1:4 1:2 1:2 1:2 1:2 1:2 1:2
19 143 1:8 1:2 1:2 1:4 1:4 1:2 1:8
20 160 1:2 1:2 1:2 1:2 1:2 1:2 1:2
21 161 1:2 1:2 1:2 1:2 1:2 1:2 1:2
22 163 1:2 1:2 1:2 1:2 1:2 1:2 1:2
23 168 1:2 1:2 1:2 1:2 1:2 1:2 1:2
24 170 1:2 1:2 1:2 1:2 1:2 1:2 1:2
3.4.2 Response of foals to the first African horse sickness vaccination
There was wide variation in the response of each foal to each of the seven serotypes in
the vaccinat ions and in the antibody titre levels of Serotypes 5 and 9. The reaction to
Serotype 1 was the most positive and the main part of the discussion will focus on this
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result and possible methods of achieving the same level of reaction for the other
serotypes. The variation in the response of the mares and foals to the seven serotypes
in the vaccinations is illustrated in Figure 3.9. The response of the foals is shown at four
different points in time: 12 hours of age, four or six weeks of age, eight weeks after the
first vaccination and eight weeks after the second vaccination. The mares have the
most negative antibody titres to Serotype 2 and no negative antibody titres to Serotype
8. The foals exhibited a similar pattern with few positive antibody titres to Serotype 2,
and many positive antibody titres to Serotypes 5, 6 and 8 at the 12 hours sampling. This
is expected, since the foal's immunity at this age is a reflection of the antibodies they
received in the colostrum, as their own immune systems are not yet fully functional.
Although Serotype 5 is not in the vaccine, the mares did show positive antibody titres for
this serotype (either through cross protection from Serotype 8 or natural exposure).
Figure 3.9 Differences in antibody titres as shown by the percentage of positive
results for the mares (within 30 mins of birth) and at four points in time for
the foals; • Mares, • Foals 12 hours, Foals 4/6 weeks old, • Foals 8
weeks after Vaccination 1, • Foals 8 weeks after Vaccination 2
By the time the foals were four to six weeks old, the proportion of negative antibody titres
had increased for all serotypes. Serotype 3 had the greatest proportion of negative
antibody titres at this stage while Serotype 6 had the lowest proportion of negative
antibody titres. In this trial, the foals showed no positive antibody titres to Serotype 4
eight weeks after Vaccination 1, and only three positive antibody titres (12.5 % of foals)
.eight weeks after Vaccination 2. There were also no positive antibody titres for
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antibodies against Serotypes 3, 6, 7 and 9 eight weeks after Vaccination 1.
Vaccinations 1 and 2 resulted in 58 % and 75 % positive antibody titres to Serotype 1,
respectively. Perhaps surprisingly , Vaccination 2 was followed by 33 % positive
antibody titres for Serotypes 5 and 9 (there were 16.67 % positive antibody titres for
Serotypes 6 and 8, the cross protective serotypes for Serotypes 9 and 5, respectively)
since they are not included in the vaccinat ion. Serotypes 5 and 9 will not be discussed
further for this reason.
Table 3.4 shows the virus neutralisation results for Serotype 1, with the first born (older)
foals on the right hand side of the table. Each column represents one foal, with the
sequential samples running down the column. The blue-coloured blocks indicate
positive antibody titres and the yellow blocks represent negative antibody titres (an
antibody titre of less than 1:32). The white squares show where no samples were taken.
The fourth and fifth lines of Table 3.4 show the number of days between the mare's
vaccination and the birth date and the age at first vaccination for each of the 24 foals
respectively. Of particular importance, as will be discussed later, is the fact that all the
mares were vaccinated on the same day, irrespective of the anticipated foaling date, and
all the foals were vaccinated on the same day, irrespective of age. This means that
there is a perfect negative correlation (-1.0) between the age of the foal at first
vaccination and the length of time between the mare's vaccination and the birth of the
foal. Therefore, the foals that were born early in the season are associated with a short
gap between the mare being vaccinated and their birth, whilst they are the oldest foals
when vaccinated themselves. The rows labelled Vaccination 1 and Vaccination 2
illustrate when the foals were vaccinated with the vaccine combination containing the
relevant serotype (AHS 1 or AHS 2). Serotype 1 is shown in Table 3.4 while the other
eight serotypes are presented in Appendix 6. The other half of the vaccine combination
(AHS 1 or AHS 2) would have been given three weeks later for Serotypes 1, 3 and 4,
and three weeks earlier for Serotypes 2, 6, 7 and 8.
There are two clear areas of negative results (yellow blocks). The first occurs after the
foals which were the youngest when first vaccinated (i.e. the left of the table) have been
vaccinated for the first time. This group of foals (1 to 7) was born at least three and a
half months after the mares had been vaccinated. The second area of negative results
is on the right hand side of the table, where the first born (older) foals appear to lack
maternal immunity. This group of foals (21 to 24) was born within six weeks of the mare
being vaccinated. Although not as clear (there are more negative results), the pattern is
repeated for the other eight serotypes (Appendix 6). The poor level of immunity in these
two groups thus appears to be related to the time between the mare being vaccinated
and the foal birth and/or the age at which the foal was vaccinated for the first time. Foal
24 does not fit the pattern as the only positive antibody titres this foal had were at one
and two months of age for Serotype 6 and at 13 months of age for Serotype 5.
Table 3.4: Virus neutralisation results forAHS Serotype 1
ZST result + + + Weak + Weak + + + + + + + + + + + + + + + - - + + Weak +
GC result + + + Weak + + + + + + + Weak + + + + + + + Weak + + +
Foal number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Davs : mare vac to foaling 138 134 129 120 117 112 107 104 98 97 95 95 81 75 73 72 69 64 60 43 42 40 35 33
Foal age at vac I (days) 65 69 74 83 86 91 96 99 105 106 108 108 122 128 130 131 134 139 143 160 161 163 168 170
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The combined effects of the time between the mare being vaccinated and the foal's birth
and that of the mare's antibody titre on the foal's antibody titre at four to six weeks of age
are shown in Figure 3.1Oa and Figure 3.1Ob. Two figures are used to illustrate this point,
as the three dimensional aspect may not be easily interpreted . The superimposed plane
in Figure 3.10a illustrates that as the mare's antibody titre decreases and the interval
between the mare's vaccination and foal birth decreases, so the foal's antibody titre
decreases when tested between four and six weeks of age. This is also shown by the
contours in Figure 3.1Ob. Those foals (21 - 24) born within six weeks of the mare being
vaccinated, do not appear to have received any maternal antibodies to the AHSV.
Interestingly though, the ZST test was positive for Foals 22 and 23, and a weak positive
for Foal 24, indicating that these foals had achieved a successful transfer of passive
immunity. Foal 21 had a negative result for the ZST test but the pattern of response to
the vaccinations is the same as for Foals 22 to 24. This negative result for antibodies for




























Figure 3.10a The effect of i) the mare's anti-African horse sickness Serotype 1
antibody titre and ii) the days between the mare's vaccination and the
foal's birth on the foal 's African horse sickness Serotype 1 antibody
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Figure 3.1Ob The effect of i) the mare's anti-African horse sickness Serotype 1 antibody
titre and ii) the days between the mare's vaccination and the foal's birth
on the foal's African horse sickness Serotype 1 antibody titre at four to six
weeks of age ; 1= 1:2, 2=1:4, 3=1 :8,4=1:16, 5=1 :32, 6=1 :64, 7=1: 128,
8=1 :256 .
Figure 3.11 illustrates the foal antibody titre on the day of vaccination with the age of the
foal at first vaccination. The lower antibody levels are found in the older foals on the day
of the vaccination. Whether the low antibody titres in the older foals are due to the age
of the foal per se, or the short interval between the mare's vaccination and the birth of
the foal cannot be answered conclusively from this trial (except for Foals 21 to 24, which
did not have a positive ant ibody titre at one month of age) , since all the mares, and
subsequently the foals, were vaccinated on one day by the stud farms involved.
Nevertheless, the lack of maternal immunity in the slightly older group of foals (15 to 20),
for periods of up to sixteen weeks (from fading of maternal immunity to positive antibody
titre after vaccination) (Table 3.5) leaves this group vulnerable to African horse sickness
and raises questions about the practice of blanket vaccination on a single day.
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Figure 3.11 The effect of foal age (days) at first vaccination on the antibody titre on the day of the first vaccination
(Serotypes: 1 +,2 El, 3 ,4 , 6 ., 7 +, 8 - ).
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Table 3.5: Virus neutralisation antibody titres for selected foals (15 - 20) to illustrate the
relationship between the time between the maternal immunity fading and a
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The antibody status of the foal on the day of the first vaccination is another factor that
affects the reaction to the vaccine (Figure 3.12). Only one foal had a positive antibody
titre on the day of the vaccination and still had an unchanged positive antibody titre two
months later. This foal (12) did not have any negative antibody titres for Serotype 1.
Two foals had unchanged negative antibody titres at both samplings, one of these foals
(Foal 24) had an antibody titre of only 1:2, throughout the trial period. The majority of
the foals (13; 54.2 %) had an increase in antibody titre at the sample taken two months
after the vaccination and all of these foals had a negative antibody titre on the day of the
vaccination and a positive antibody titre two months later. Of the remaining eight foals,
three (12.5 %) had a positive antibody titre on the day of the vaccination and a negative
two months later and the last five (20.8 %) had negative antibody titres for both samples,
with a decrease in antibody titres between the samples. This indicates that the foal has
a greater chance of reacting to the vaccination if the antibody titre has dropped to a
negative antibody titre before the vaccination is administered. This pattern changes
from the majority of the foals ending with a positive antibody titre to the majority of the
foals having an unchanged antibody titre when all the serotypes are included in the

































Figure 3.12 The effect of the foal's antibody titre for Serotype 1, on the day of
Vaccination 1, on the subsequent reaction to the vaccination, as shown by
the change in antibody titre two months from vaccination day.
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Figure 3.13 The effect of the foal's antibody titre (all serotypes) on the day of
Vaccination 1 on the subsequent reaction to the vaccination, as shown by
the change in antibody titre two months from the day of vaccination.
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The greater chance of a positive reaction to the vaccination if the antibody titre is a
negative before the vaccination is also illustrated when a group of seven foals is
tracked" (for Serotype 1, Figure 3.14) from before vaccination to 12 weeks after the
vaccination. It can be seen that the anti-AHSV antibody titres of the two foals with a
positive antibody titre on the day of vaccination dropped after vaccination, while the
antibody titres of the other three foals increased. However, for a few of the foals (four for
Serotype 1) the antibody titres did not rise after the vaccination. The decrease in
antibody titre after vaccination indicates that there is a reaction between the existing
passive immunity in the foal and the live virus in the vaccine. The virus and the maternal
antibodies possibly react and no new antibodies are produced due to the negative
feedback effect of the presence of the passively transferred antibodies (Tizard, 2000).
Immune responses are in part regulated by a negative feedback system, the presence of
IgG antibodies depresses the production of IgM and IgG, while the presence of IgM
antibodies depresses the further synthesis of IgM (Tizard, 2000). A specific antibody will
tend to suppress a specific immune response better than non-specific immunoglobulin.
Antibodies from maternal immunity have the same effect (Tizard, 2000), hence the poor
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Figure 3.14 Foal antibody titres contrasting the response of foals to the vaccination
with positive and negative antibody titres at vaccination;
• Foal 1; • Foal 2; ... Foal 8; 4» Foal 9; x Foal 11; + Foal 14; * Foal 19.
15
These seven foals were chosen to illustrate each of the reaction patterns for Serotype 1.
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A possible theoretical explanat ion for the pattern of the foals' reactions to the vaccination
is that the virus from the vaccinat ion given to the mare is still alive in the mare and is
transmitted at birth to the foals born early in the season (Le. foals born within 3 months
of mare vaccination; Foals 12 to 24) (Weber, 2004, pers. Comm.) , or that remnants of
the virus are transmitted to the foal and act as an antigen. This would mean that the
antigen and the maternal antibodies would react in the foal, and the very first foals of the
season (those born within 2 months of mare vaccination ; Foals 19 to 24) would appear
to receive no immunity from the mares. The next group of foals ; born two to three
months after the mare vaccination (Foals 12 to 19), would still retain some of the
maternal immunity and the last foals born (Foals 1 to 11) would not be affected by the
antigen. This infection at birth, in foals born to mares vaccinated late in pregnancy,
would be the foal's initial exposure to the antigen and the foal's own immune system will
register the antigen, thereby improving the subsequent reaction to the vaccination . The
vaccination will therefore effectively be the "booster" rather than the initial exposure to
the virus. If the foals are being exposed to the antigen at birth then, although the first
foals (Foals 19 to 24) appear to be unprotected in the post parium period, the reaction to
further exposure to the virus will result in a prompt immune reaction as demonstrated by
the reaction to the vaccination . However, this is still not an ideal situation as the reaction
may not be prompt enough for complete protection and some foals may still be lost. The
foals born slightly later, two to three months after mare vaccination (Foals 12 to 19),
have the best protection as they retain some of the maternal immunity and react to the
first vaccination.
For the foals born at the end of the season (Foals 1 to 11), the vaccination will represent
the initial exposure to the live virus. These foals can be further split into two groups.
The first is the foals born more than three months after the mare was vaccinated and
older than three months at first vaccination (Foals 6 to 11). The second is the foals born
more than 3 months after the mare was vaccinated and less than three months old at
first vaccination (Foals 1 to 5).
The first group of foals (Foals 6 to 11) will react to the vaccine as the maternal immunity
will have faded before they are vaccinated and they will therefore have some protection
after the first vaccination. The final group of foals (Foals 1 to 5) will have retained the
antibodies from the mare. These antibodies will react with the virus in the vaccine
causing a decrease in the antibody titre rather than the expected increase . These foals
are thus protected from birth until the first vaccination but are subsequently unprotected.
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3.4.3 Response of foals to the second African horse sickness vaccination
Only three of the nine foals with no reaction to the first vaccination reacted to the second
vaccination for Serotype 1 (Table 3.4). There are two possibilities for the lack of reaction
to the second vaccination in foals less than three months at first vaccination . As there is
little known about the immune status of equines (Mullins, pers. comm., 2006) either
possibility or a combination could be the reason. The first is that the first vaccination
was given too early and the passive immunity received from the mare possibly interfered
with the reaction to the vaccine , and this effect continued to the second vaccination. The
second possibility is that the second set of vaccines is given too long after the first. The
second vaccination is thus not acting as a booster but rather as the primarx vaccination
again (Weber, 2004, pers. comm.). Newborn animals are capable of an immune
response at birth. However, the primary response is limited with a long lag period and
low antibody concentrations (Tizard, 2000). The response to the booster or second
exposure is faster and greater due to the presence of already formed memory cells
(Tizard, 2000). Immunoglobulin M and IgG are the two most important immunoglobul ins
in the development of immunity (reaction to vaccination) (Tizard, 2000). Some IgM is
present in the serum of the foal when it is born (Tizard, 2000). Immunoglobulin G and
IgM are antibodies that are formed during active immunity, and are part of the B cell
response to an antigen : When the body is exposed to an antigen for the first time, B
cells are activated and divide into three types of cells - IgM producing B cells (majority),
some IgG producing B cells and memory B cells (Figure 3.15). When the same antigen
is encountered again, the memory B cells are activated producing mainly IgG, some IgM
and more memory B cells. This secondary response is much greater than the primary
response and the lag period is shorter as more antibodies are produced and the antigen
is detected sooner (Tizard, 2000). After each vaccination, the base of memory cells
from the previous vaccination will be built on. Demonstrable antibodies to all the
serotypes may only be present after three or four vaccinations (Gerdes, pers. comm.,
2005). The more effective the vaccination programme , the quicker this will occur. The
tests measure the circulating or humoral antibodies, but there is also an unmeasured
cellular response providing protection against AHS (Gerdes, pers. comm., 2005).
The poor response to the second vaccination could be because the time period between
the two sets of vaccinat ions is too great and so the second set of vaccinations may be
acting as an initial exposure to the virus again, rather than as a booster exposure. The
multiple serotypes complicate the vaccination programme as there is not an equal
reaction to all of the serotypes. The best reaction will be to the most immunogen ic strain
in the vaccine (this appears to be Serotype 1 in AHS 1 and Serotype 2 in AHS 2 for the
work reported here as is shown by the number of foals with a positive antibody titre at
the end of the trial period, Table 3.6) and, as the attractiveness of a serotype to the
immune system decreases, so will the reaction to that serotype (Tizard, 2000).
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Stressors will also reduce the ability of the immune system to react to the vaccine
(Tizard, 2000) and the foals are generally under some stress when they are vaccinated
as they are not fully used to being handled and, in general, other vaccinations and
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Figure 3.15 The time course of a B-cell response and the cellular events that
accompany it. Note how some IgG is made in the primary immune
response while a little IgM is made in the secondary immune response,
(Tizard,2000)
Table 3.6 The number of positive and negative antibody titres at the end of the trial
period for each of the nine AHS serotypes . .




























The package insert for the vaccinations (Appendix 4) states that immunity starts to
develop two to three weeks after inoculation and protection against some of the virus
serotypes is achieved after four weeks. Figures 3.16 and 3.17 show the large variation
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in the time taken to develop a positive antibody titre after Vaccinations 1 and 2,
respectively. Some of the foals only achieved a positive antibody titre after the immunity
of other foals had already started to wane. The variation in the number of positive
reactions between serotypes, and the time taken to develop a positive antibody titre are
also evident. Vaccination 2 resulted in a positive antibody titre in a shorter period of
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Figure 3.16 Time from first vaccination to positive antibody titre as shown by the
percentage of new positive antibody titres in foals previously testing
negative (note: no positive antibody titres for Serotypes 3 and 7);
. 4 w, . 6 w, 8 w, 10 w, . 12 w, m14 w, . 16 w, a is w,. 20 w, .
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Figure 3.17 Time from second vaccination to positive antibody titre as shown by the
percentage of new positive antibody titres in foals previously testing
negative (note: no positive antibody titres for Serotypes 3 and 7);
• 4 w, • 6 w, 8 w, 10 w, • 12 w
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3.4.4 Overall reactions and patterns
Figure 3.18 shows the different time lines for vaccination and antibody development for
three foals from mare vaccination until the last sample taken ; for the second foal from
eitherend of the foaling season (i.e. second oldest and second youngest foal on the day
of the first vaccination) and for a foal from the middle of the season (born 73 days after
the mare vaccination and 130 days old when vaccinated for the first time. Foals 2 and
23 were chosen instead of 1 and 24 because Foal 24 does not fit the pattern (as
discussed previously); Foal 15 was chosen because it has the best protection overall.
Foal 2 is representative of the foals born late in the season, with some level of maternal
immunity, a positive antibody titre when first vaccinated and no response to either of the
vaccinations.
The time line, with respect to maternal and foal vaccinations, experienced by the foal 15
resulted in the best protection for the foal against Serotype 1 when compared to the
other foals. This foal also had the best protection (when compared to the other foals)
against Serotypes 3, 6 and 7. It had a good level of protection against Serotypes 2 and
9, but no positive results for Serotypes 4, 5 and 8. The antibody titres at each sampling
for this foal from six weeks ofage are shown in Figures 3.19, 3.20,and 3.21. Figure 3.19
shows Serotypes 1, 3, 6 and 7; Figure 3.20 shows Serotypes 2 and 9 and Figure 3.21
shows Serotypes 4, 5 and 8.
Although foal 15 had no positive antibody titres for Serotypes 4, 5 and 8, two foals within
the same group outlined in the discussion about Table 3.4 had the best pattern of
protection. The foal with the best pattern of protection for Serotypes 4 and 5 was Foal
14 and for Serotype 8 was Foal 13. These foals are within the same group outlined in
the discussion about Table 3.4; i.e. those foals born two to three months after the mare
vaccination and about four months of age when vaccinated for the first time. This group
of foals (Foals 12 to 19) demonstrate that positive results from the vaccine are possible,
but the recommendations for the vaccination programme may need revising and any
recommended programme must be adhered to. There are positive antibody titres
outside of this group of foals for some of the serotypes , but at least one foal in this group
had a positive antibody titre at the end of the trial for each serotype , and the majority of
the foals with positive antibody titres at the end of the sampling period.
Foal 23 is representative of the first foals of the season, with no passive immunity; a
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Figure 3.18 Time frames and response of three selected foals (Serotype 1).
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Figure 3.19 Anti-AHSV antibody titres for foal 15 from six weeks of age to end of the
trial period for Serotypes 1, 3, 6 and 7 (green points are when the foal
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Figure 3.20 Anti-AHSV antibody titres for foal 15 from six weeks of age to end of the
trial period for Serotypes 2 and 9 (green points are when the foal was
vaccinated) (Serotypes: 2 · , 9 - )
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Figure 3.21 Anti-AHSV antibody titres for foal 15 from six weeks of age to end of the
trial period for Serotypes 4, 5 and 8 (green points are when the foal was
vaccinated for each serotype) (Serotypes: 4 ,5 *, 8 - )
The effect of the time gap between the mare's vaccination and the foal being born and
the foal's age at first vaccination on the foal's response to the vaccinations have already
been covered in this discussion. The recommendation for a vaccination program needs
to take these factors (the timing of the vaccinations including the mare's vaccination date
and the foal's age at first vaccination) into account to try to achieve the ideal pattern of
response for all of the foals . Vaccinating all the mares and, subsequently, all the foals
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on a single day will result in the greatest possible range of reactions and may result in
more animals than necessary being unprotected. The principle of herd immunity is that
the individual animal is at the greatest risk when the proportion of susceptible animals in
the herd is high, while the susceptible individual is indirectly protected when the
proportion of susceptible animals is low. The principle of herd immunity works well when
the majority of the animals are protected (Tizard, 2000) but a vaccinat ion program
should strengthen the herd immunity rather than relying on the herd immunity for
protection of the animals within the herd.
On the basis of the work reported here, a revised vaccination schedule is recommended
in which the mare would be vaccinated annually at three months and two months prior to
her expected foaling date, with African horse sickness AHS 1 and AHS 2, respectively.
The foals would then be vaccinated at four and five months of age with African horse
sickness AHS 1 and AHS 2, and then again at six and seven months of age. This
should give the majority of the foals the same pattern of reaction as discussed for Foal
15, in which they are protected from birth until the first vaccination by the maternal
immunity but the maternal immunity would have decreased sufficiently to allow a
reaction to take place to the first vaccination. The second vaccination will then be at the
correct time to act as a booster vaccination and to give the foals a longer lasting
immunity. The second vaccination needs to be close enough to the first vaccination to '
act as a booster, but still sufficiently spaced so that the negative feedback effect of the
presence of antibodies to the virus will not reduce the response to the vaccine. This
revised vaccination schedule is based on the results of the trial reported here, in which
the maternal immunity had decreased to a sufficiently low level to have allowed the first
vaccination by four months of age. The time between the vaccinations has been
decreased, as in the reported trial the second dose did not appear to be acting as a
"booster" vaccinat ion should , but rather as a primary vaccination
Any revised vaccination schedule should be based on the expected foaling date for each
mare and the age of each foal. It could be based on the dates for a group of mares and
the ages of a group of foals (dates and ages within a month of each other). Vaccinating
all the animals on a farm on the same day may make management easy but this means
that there is a large reliance on herd immunity protecting the individual, since this system
results in wide deviations from the recommended vaccination schedule . The case study
used in this discussion and many of the other principles discussed have shown that
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The literature review looked at the passive transfer of immunity from the mare to the foal.
The newborn foal is at risk from the development of infections as it adapts to its new
environment. The risk is decreased by the passive transfer of immunity from the mare
through colostrum. This immunity protects the foal until its own immune system is fully
functional. Factors affecting the transfer of passive immunity and the consequences of
failure of passive transfer of immunity were discussed. The importance of testing for the
transfer of passive immunity and different methods of testing whether the transfer of
passive immunity has occurred were reviewed. Each test method and its associated
advantages and disadvantages were described . Passive immunity affects vaccination
programmes, as the presence of maternal antibodies inhibits the active immune
response. This means that passive immunity affects the timing of the first vaccination in
two ways. Firstly, the vaccination will only be effective when the passive immunity has
faded sufficiently to allow an active response but, secondly, the vaccination should not
be given after the passive immunity has declined to non-protective levels. The review
concluded with a discussion of vaccination programmes using African horse sickness as
an example.
Trial One looked at several different, locally available, methods of testing for the transfer
of passive immunity . The tests investigated were the measurement of the colostral
specific gravity, the measurement of total serum protein by the refractometer and the
measurement of serum immunoglobulin G by the zinc sulphate turbidity (ZST) and
glutaraldehyde coagulation (GC) tests. The results of these methods were compared to
the results of the measurement of immunoglobulin G by the single radial
immunodiffusion test (SRID).
The single radial immunodiffusion test is the benchmark test for immunoglobulin testing,
and represents the ideal test to use as it gives a quantitative result and is not subjective.
However, the test takes too long to complete for routine use in newborn foals , since the
gastrointestinal becomes impermeable to immunoglobulins within approximately 18 to 24
hours of birth. This means that treatments for failure of transfer of passive immunity
need to be given very soon after birth. The specific density of colostrum was shown not
to be a good predictor of the transfer of passive immunity. However, the colostrum
specific density test should still be used to test the colostrum that is going to be stored
for use in treating failure of passive transfer. There were significant correlations in the
values for IgG status between the three inexpensive tests and the SRID test (colostrum,
p=O.1; refractometer, GC and ZST, p=O.01). The ZST and GC tests express IgG status
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in categories, relative to the critical IgG levels of 400 and 800 mg IgG/dl serum . The
refractometer yields a quantitative test result, allowing regression analys is to be used to
give a prediction of the SRID result from refractometer readings . This analysis suggests
that refractometer readings of 6.30 and 6.58 equate to SRID readings of 400 and 800
mg/dl, respectively. Chi-squared analysis of the GC, ZST and refractometer results
showed there to be a significant relationship (p=0.1) between observed and expected
IgG values for all three tests.
Over- and under-estimation of IgG status (% samples, compared to the SRID test
results) were found to be, respectively , 7.04 and 2.82 (GC), 11.97 and 4.93 (ZST) and
12.68 and 0.7 (refractometer). The fina l choice of the ZST, GC or refractometer tests as
the foal-side test will have to be decided on by the stud manager and veterinarian , taking
into account local conditions but the recommendation of the author would be to use the
GC test. The current recommendation to test the foal six hours after birth and to treat
before 18 hours of age with colostrum remain valid. The age of the mare, parity of the
~
mare and the gestation length did not appear to affect the transfer of immunity from the
mare to the foal.
Trial Two looked at the African Horse Sickness vaccination programme, focusing on
when to vaccinate foals for the first time and what factors affect the response of the foa ls
to the vaccine. A recommendation was made that management practices need to
change in order to adhere more closely to the vaccination schedule recommended by
the manufacturer. Suggested revis ions to the existing vaccination schedule were also
presented. The revised vaccination schedule is as follows : the mare should be
vaccinated at three and two months prior to her expected foaling date with AHS 1 and
AHS 2 respectively. The foal would then be vaccinated at four and five months of age
with AHS 1 and AHS 2 and then again at six and seven months of age (AHS 1 and AHS
2).
The results of this work have raised many questions and there is little doubt that further
. research is needed into the response of animals in the field to available vaccines.
Adjusting the current vaccination programme is only a start in the battle to protect South
African horses as fully as possible against AHS .
Specific questions that further research should aim to answer are :
1) The effectiveness of any revised or proposed vaccination programmes (from
foals to mature animals) .
2) Should the vaccine be split further into monovalent vaccines or polyvalent
vaccines with fewer serotypes?
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3) How long before the expected foaling date should the mare be vaccinated in
order for antibodies to be present in the colostrum?
4) How long does it take to transfer AHSV antibodies into the colostrum and does it
differ for the different serotypes?
5) When should the third set of vaccinat ions take place?
6) Is the virus from the vaccine being transferred to the foal at birth?
This thesis makes available valuable field data on the effectiveness of the African horse
sickness vaccination under practical conditions in the KwaZulu-Natal Midlands. It is
hoped that, beyond the recommendations made above, other researchers will be able to
make use of the data presented in the Appendices attached to this work to help design
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APPENDIX 1
SINGLE RADIAL IMMUNODIFFUSION PROTOCOL
This is the package insert that comes with the Single Radial Immunodiffusion test kits.
A1.1 Kit contents
1) Ready to use single radial immunodiffusion (SRID) plates containing
monospecific antisera in buffered agarose.
2) Reference standards (0.09% Sodium Azide).
3) Instruction sheet with graph paper.




Test tubes if dilutions are necessary.
Samples to be tested. Specimens should be collected by approved
veterinary techniques. Allow the blood to clot, and centrifuge to collect
serum. Use serum within 72 hours, or freeze until ready to assay. Avoid
repeated freezing and thawing.
A1.3 Precautions
Store plates in an inverted position at 4-8°C. DO NOT FREEZE. Keep the plate tightly
closed at all times. Between uses, plates may be stored inverted in their zip lock bags.
The expiration date is listed on the outside package label.
For Veterinary Research Use Only
A1.4 Procedure
Add reference standards by carefully pipetting 3 microliters of each into the first wells.
To use the micropipetting system, insert the reusable plunger into the end of the
disposable micropipette marked by the yellow band. Depress the plunger to the other
end of the micropipette. Draw the standard up to the black line marked on the
micropipette. Insert the pipette into the well to be filled and depress the plunger. Be
sure to lift the pipette off the well bottom once the filling process has begun. The pipette
may then be discarded.
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. Pipette 3 microliters of the specimen(s) to be tested into the remaining wells.
Replace the cover firmly on the plate and leave undisturbed, right side up at room
temperature for 18-24 hours outside of its zip lock bag.
After 18-24 hours, the diameters of the rings may be read and a standard curve
established. Measure each diameter either directly off the plate or by using an
inexpensive comparator . Read each diameter in terms of mm. If all wells are not used,
replace the lid securely and' store at 4-8° C inverted in the zip lock bag provided.
Plot the diameters of the reference standards versus the concentrations of the reference
standards as indicated on the supplied graph paper. Draw a standard curve.
. Alternatively, a calculator with the capability of establishing a regression line may be
used to determine the concentrations of the unknowns. Specimens with diameters
beyond the range of the standard curve may be retested either by redilution if the rings
are too large or by concentration if the rings are too small.
Do not freeze!
Store inverted at 4-8°C
A1.5 Interpretation
Information sheets regarding immuno-deficiencies and immunoproliferative disorders of
horses, cows and dogs are available through VMRO, Inc. (Section A1.8).
A1.6 Principles
The technique of single radial immunodiffusion (SRID) is the most widely used method
for quantitative determination of classes of immunoglobulins and other serum and
plasma proteins; This technique combines rapid and easy sample application with a
high degree of accuracy and reproducibility .
The method is derived primarily from the works of Fahey, and of Mancini. Antiserum
specific for the protein to be measured is incorporated into agarose gel. The sample
antigen diffuses into the gel containing the antibody, and a ring of precipitation forms that
is proportional in size to the concentration of the antigen (Figure A1.1). A linear
relationship exists between the diameter of the ring and the concentration of the antigen
when plotted on semi-log graph paper. This method is time and temperature dependant.
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Figure A1.1 Single radial immunodiffusion test plate
Ai.7 Limitations
Results are limited by the assay range of the kit, although dilution of the specimen to be
tested will extend the range. When diameters greater than the highest reference
standard occur, dilute the sample and rerun the assay. If the diameter of the ring is too
small, the sample may be concentrated.
Ai.8 Equine information sheet
VMRD, Inc's radial immunodiffusion plates are ready-to-use with standards calibrated to
determine samples within the normal range. Custom plates can be prepared to meet
your specific needs.
Prevalence of Immunodeficiency Disorders
FPT and partial FPT:
CID:
Selective IgM Deficiency:
as high as 20% of all foals, the percentage varies
depending on neonatal foal management
2.3% of all Arabian foals
unknown; 19 of 2,092 submissions
Agammaglobulinem ia; unknown; 3 of 2,092 submissions
Transient hypogammag lobulinemia: unknown; 2 of 2,092 submissions
Selective IgA Deficiency: unknown
Lymphosarcoma with paraproteins: unknown
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Normal Equine Immunoglobulin Values
No. of Ref. IgG (T)Age Breed No.
IgA IgG IgM
An imals
Serum (mg/dl +/- S.D.)
1 - 20 days Arabian 28 1 21 +/-13 814+/-583 143+/-88 28+/-11
1-13days Arabian 37 2 38+/-14 944+/-523 171 +/-94 31 +/-1 0
1 -14 days TB 66 3 ND 1335+/-652
.
ND ND
21 - 40 days Arabian 22 . 1 17+/-13 480+/-293 126+/-41 30+/-10
41 - 60 days Arabian 19 1 20+/-6 264+/-193 96+/-33 42+/-12
61 - 80 days Arabian 9 1 25+/-10 252+/-128 75+/-17 36+/-12
·81 -140 days Arabian 15 1 64+/-28 248+/-92 162+/-126 39+/-15
3 - 5 months Mixed 27 4 38+/-14 380+/-188 211+/-148 61+/-22"
6 -12 months TB/Mixed 95 NA ND 863+/-298 NO 50+/-16
Adults Shetland 20 6 153+/-86 1334+/-350 821+/-310 120+/-31
Tears (mg/dl)
Adults Shetland 4 6 135 15 3 0 -5
Milk (mg/dl)
Horse NA 10 50 - 100 20 - 50 5 - 20 5 - 10
Postpartum Presuckle Colostrum
TB 32 4 Ig8: mean =2354; range =1080 - 8960
* This Ig8 value is higher than other data for similarly aged foals because all foals with
less than 400 mg/dl were diagnosed as failures and removed from the normal data.
** Since most selective IgM deficiencies are diagnosed between 3-5 months, an IgM
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APPENDIX 2
RESULTS TABLES OF TESTS FOR IMMUNOGLOBULIN G (lgG)
Table A2.1: Details of the mares
Mare No. Colostrum Refractometer ZST GC
SRID Age Parity Gestation length Foal 12 hr SRID
(mg/dl) (mg/dl) (years) (No. of foals) (days) (mg/dl)
1 9 + >800 1299 15 10 334 1969
2 10 + >800 1969 7 3 344 3591
3 8 + >800 2160 6 1 350 2160
4 1.06 -1 .09 9 + >800 1579 9 4 351 2507
5 »1 .09 9.5 + >800 1773 13 7 355 1253
6 1.08 9 + >800 2507 9 3 342 790
7 »1 .10 9 + >800 2369 11 8 343 1492
8 >1 .09 8.8 + >800 3761 11 4 351 4738
9 1.08 9.2 + >800 2369 10 4 327 2659
10 1.08 9.2 + >800 2369 11 6 352 5443
11 1.06 8.8 + >800 2160 7 1 339 1361
12 1.06 8.6 + >800 1492 8 4 353 1080
13 1.07 10 + >800 1637 14 6 334 3761
14 1.08 8.2 + >800 2369 5 1 355 1492
15 1.10 9 + >800 1880 5 1 334 1425
16 >1 .10 9 + >800 2262 6 1 338 1425
17 1.10 8 + >800 1492 7 3 341 1299
18 1.09 9 + >800 1880 7 1 348 3429
19 1.08 9 + >800 2062 13 7 347 3591
20 1.07 8 + >800 3591 15 8 338 3429
CD
o
Table A2.1 (continued): Details of the mares
Mare No. Colostrum Refractometer ZST GC SRID
Age Parity Gestation length Foal 12 hr SRlD
(mg/d l) (mg/dl) (years) (No. of foals) (days) (mg/dl)
21 1.04 9.6 + >800 1563 11 6 353 1563
22 1.09 9.6 + >800 3938 11 3 333 3761
23 >1.10 8.8 + >800 940 10 3 347 2262
24 <1.00 9.4 + >800 1714 15 6 334 620
25 1.03 9 + >800 1425 6 1 318 898
26 1.08 9.6 + >800 2262 10 5 344 1425
27 1.06 10 + >800 2062 12 6 343 2481
28 1.07 9.8 + >800 1637 12 5 344 2262
29 1.10 9.8 + >800 1880 11 4 353 1492
30 1.04 10.6 + >800 2262 14 6 341 790
31 >1.10 10 + >800 2369 20 8 349 2062
32 1.09 9.4 + >800 2160 9 3 343 3591
33 1.08 10.6 + >800 3591 14 5 338 4320
34 1.06 9.4 + >800 2369 11 6 346 3591
35 1.05 9.8 + >800 2160 12 5 346 940
36 1.09 9.8 + >800 1563 16 7 338 1637
37 1.06 8.4 + >800 2062 13 2 346 1131
38 1.05 9.2 + >800 2369 11 6 338 90
39 1.07 10 + >800 1969 12 7 343 2062
40 1.05 10.6 + >800 3591 15 6 341 1969
CD
->.
Table A2.1 (continued): Details of the mares
Mare No. Colostrum Refractometer ZST
GC SRID Age Parity Gestation length Foal 12 hr SRID
(mg/dl) (mg/dl) (years) (No. of foals) (days) (mg/dl)
41 1.07 9.2 + >800 2369 6 1 349 1361
42 1.07 10.2 + >800 2160 12 7 332 1080
43 »1 .10 9 + >800 2062 10 2 338 2369
44 >1.10 9.4 + >800 2262 12 6 339 3591
45 1.08 8 + >800 1880 6 1 358 1637
46 1.00 8.2 + >800 1425 15 7 342 497
47 1.06 9 + >800 1361 5 2 329 857
48 1.08 9 + >800 1361 11 6 345 2062
49 1.09 8.6 + >800 1031 7 3 341 1714




Table A2.2 : Foal details
Foal and Age (hours) Refractometer ZST GC (mg/d l) SRID (mg/dl)
sample no. at sampling
1.1 8 7 + > 800 1131
1.2 16 8 + > 800 1969
1.3 32 8 + > 800 2160
2.1 6.5 9 + > 800 2369
2.2 14.5 9 + > 800 3591
2.3 30.5 9 + > 800 3429
3.1 7 7 + > 800 1425
3.2 15 7 + > 800 2160
3.3 31 7 + > 800 1880
4.1 12 8 + > 800 2507
4.2 24 7.5 + > 800 1990
5.1 22 7.5 + > 800 1254
6.1 12 6 + 400-800 790
6.2 20 6 weak + 400-800 790
6.3 36 6 weak + 400-800 665
7.1 11.75 8 + > 800 1492
7.2 19.75 8 + > 800 1492
7.3 35.75 7.4 + > 800 1492
8.1 0 5.6 weak + < 400 31
8.2 9.5 8.4 + > 800 3761
8.3 16.5 8.8 + > 800 4738
8.4 33.5 8.8 + > 800 3761
9.1 11 8 + > 800 2659
9.2 19 7.8 + > 800 3591
9.3 35.5 8 + > 800 2369
10.1 8 8.2 + > 800 2481
10.2 16 9 + > 800 5443
10.3 32 9 + > 800 5700
11.1 8 6.8 + > 800 1361
11.2 28.5 6.4 + > 800 1185
12.1 7.5 6.4 + > 800 1080
12.2 31.5 6.6 weak + > 800 1080
13.1 8 9 + > 800 4125
13.2 16 9 + > 800 3761
13.3 35.5 8.8 + > 800 3591
14.1 9 7.6 + > 800 1493
14.2 33 7 + > 800 2160
15.1 5.5 6 weak + 400-800 898
15.2 9 7 weak + 400 -800 1425
15.3 29 .5 7 + > 800 2985
16.1 7.5 6.2 weak + 400 -800 · 1425
16.2 28 8.2 + > 800 4320
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Table A2.2 (continued): Foal deta ils
Foal and Age (hours) Refractometer ZST GC (mg/dl) SRID (mg/dl)
sample no. at sampling
17.1 7.5 6.8 + > 800 1714
17.2 15.5 7.6 + > 800 1299
17.3 35.5 7.6 + > 800 1425
18.1 8.75 7.2 + > 800 898
18.2 12.75 8 + > 800 3429
18.3 28.75 7.8 + > 800 3429
19.1 5 7 weak + > 800 1031
19.2 25.75 8.4 + > 800 3591
19.3 49.75 8.2 + > 800 3761
20.1 23 7.8 + > 800 3429
20.2 47 7.2 > 800 2369
21.1 7 8 + > 800 1563
21.2 31 7.2 + > 800 1714
21.3 87 7.2 + > 800 2062
22.1 6 6.4 weak + 400-800 940
22.2 14 9.4 + > 800 3761
22.3 30 9 + > 800 5970
23.1 9 8.4 + > 800 1969
23.2 17 8.4 + > 800 2262
23.3 33 8.8 + > 800 2262
24.1 8.5 6.4 weak + > 800 680
24.2 16.5 6 weak + 400-800 620
24.3 32.5 6.6 + > 800 712
25.1 7.5 6 weak + 400-800 516
25.2 15.5 6.2 + 400-800 898
25.3 31.5 6.4 + > 800 746
26.1 6.25 7.4 + > 800 1425
26.2 30.5 8.6 + > 800 2160
26.3 38.5 8.2 + > 800 2262
27.1 5.75 8.2 + > 800 3274
27.2 13.75 8 + > 800 2481
27.3 29.75 8 + > 800 2160
28.1 12.75 7.8 + > 800 2262
28.2 20.75 7.6 + > 800 2062
29.1 9.5 7.4 + > 800 1637
29.2 17.5 7.2 + > 800 1492
29.3 33.5 7.4 + > 800 1425
30.1 16.5 7 400-800 790
30.2 56.5 7 weak + > 800 866
30.3 81.5 7 weak + > 800 1254
31.1 10 7.6 + > 800 1714
31.2 18 7 + > 800 2062
31.3 34 7 + > 800 1637
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Table A2.2 (continued): Foal details
Foal and Age (hours) Refractometer ZST GC (mg/dl) SRID (mg/dl)
sample no. at sampling
32.1 7 8 + > 800 2721
32.2 15 8.2 + > 800 3591
32.3 31 8.2 + > 800 3591
33.1 7 8.2 + > 800 3591
33.2 10.5 8.4 + > 800 4320
33.3 26 8 + > 800 4738
34.1 10.5 8.2 + > 800 3591
34.2 18.5 8 + > 800 3761
34.3 34.5 8 + > 800 3761
35.1 10.5 6.8 weak + > 800 940
35.2 18.5 7. weak + > 800 898
35.3 34.5 6.8 + > 800 2160
36.1 20.5 8 + > 800 1637
36.2 28.5 7.8 + > 800 1563
36.3 44.5 7.6 + > 800 1637
37.1 7 7.2 + > 800 898
37.2 15 7 + > 800 1131
37.3 31 7.4 + > 800 1185
38.1 13.5 5.4 weak + < 400 90
38.2 36.5 5.4 + < 400 313
38.3 40.5 5.4 + < 400 286
39.1 15 7 + > 800 2062
39.2 19 7 + > 800 1969
39.3 35.5 7 + > 800 2160
40.1 13.5 8 + > 800 1969
40.2 17.5 7.6 + > 800 2160
40.3 34 7.8 + > 800 5443
41.1 12.5 7 + > 800 1361
41.2 20 7.4 + > 800 1637
41.3 40 6.8 + > 800 1795
42.1 4.5 6 400-800 1361
42.2 11.75 6.8 weak + > 800 1080
42 .3 31.75 6 + 400-800 1299
43.1 14.5 7.2 + > 800 2369
43.2 18.5 7.4 + > 800 2262
43.3 34.5 7.6 + > 800 2369
44.1 13 7.8 + > 800 3591
44.2 17 8 + > 800 2721
44.3 33 7.6 + > 800 2985
45.1 10.5 7.8 + > 800 1361
45.2 14.5 8.4 + > 800 1637
45.3 30.5 8 + > 800 1795
46.1 6 6 400-800 217
46 .2 13 6.2 400-800 497
46.3 29 6 weak + 400-800 627
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Table A2.2 (continued): Foal details
Foal and Age (hours) Refractometer ZST GC (mg/dl) SRID (mg/dl)
sample no. at sampl ing
47.1 11.5 6 < 400 857
47.2 15.5 6 weak + 400 -800 940
47.3 31.25 6 + 400-800 818
48.1 9.5 7.4 + > 800 2369
48.2 17.5 6.8 + > 800 2062
48.3 33.5 7.2 + > 800 2262
49.1 7.5 8.2 + > 800 1714
49.2 15.5 7.4 + > 800 1714
49.3 31.5 7.8 + > 800 2062
50.1 13 7.2 + > 800 2062
50.2 37 7 + > 800 1795
50.3 43 7 + > 800 1880
APPENDIX 3
ANALYSIS OF VARIANCE (ANOVA) TABLES FOR AGE, PARITY AND
GESTATION LENGTH OF MARES.
Table A3.1 : ANOVA: age
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37 · 58023455
Variate: Foal 12 hour SRID
















Not significant at the 1% level of significance
Table A3.2: ANOVA: parity
Variate: Foal 12 hour SRID
Source of variation d.f. s.s. m.s. v.r. F pr
Parity 8 6192704 774088 0.5 0.847
Residual 41 63194224 1541323
Total 49 69386928
Not significant at the 1% level of significance
Table A3.3: ANOVA: Gestation length
Variate: Foal 12 hour SRID
Source of variation d.f. s.s. m.s. v.r. F pr
Gestation length 22 36417135 1655324 1.36 0.224
Residual 27 32969792 1221103
Total 49 69386928
Not significant at the 1% level of significance
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APPENDIX 4
AFRICAN HORSE SICKNESS VACCINE PACKAGE INSERT
HORSESICKNESS VACCINE
Reg.No.G 0116 (Act 36/1947)
Namibia:NSR 0586
Freeze-dried, polyvalent, live attenuated horsesickness virus strains for the prophylactic
immunisation of horses, mules and donkeys against horsesickness.
The vaccine is presented as two separate injections with different horsesickness
virus types. First administer combination I and at least three weeks later
combination 11.
Store the vaccine in a refrigerator at a temperature of 4 °C to 8 °C.
Do not use the vaccine after the expiry date printed on the bottle.
RECOMMENDATIONS FOR USE
Foals born of unvaccinated dams can be inoculated at any age but foals of "immune
dams should not be vaccinated until they are at least six to seven months old. Animals
should preferably be immunised during early summer. Immunisation of mares should be
avoided during the first three months of pregnancy.
Annual immunisation is recommended .
It takes up to 2 - 3 vaccinations for horses to become immune to all the serotypes in the
vaccine. It is therefore important to combine vaccination with the control of the
Culicoides midges which transmit the disease. Horses can be protected from midge
bites by stabling them from dusk to dawn, using insect repellents and keeping animals
away from low-lying vlei areas or other surface water during the day.
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WARNINGS
Do not slaughter animals for human consumption within 7 days of vaccination.
Vaccinate healthy animals only.
Keep out of reach of children, uninformed persons and animals.
The vaccine will not necessarily stimulate a complete immunity in all animals and
additional measures must necessarily be taken to ensure protection
of horses against horsesickness during the time of the year when the
risk of transmission of infection by biting insects is greatest.
Although this product has been extensively tested under a large variety of
conditions, failure thereof may ensue as a result of a wide range of
reasons. If this is suspected, seek veterinary advice and notify the
registration holder.
Do not vaccinate horses more than once a year.
DIRECTIONS FOR USE
Use only as directed.
The active ingredient of the vaccine is in the form of a powder or pellet in a small bottle.
Connect one of the enclosed needles to one of the syringes with diluent and transfer the
contents to bottle nO.1. Mix thoroughly until the powder is dissolved and withdraw the
contents into the syringe. The vaccine is now ready for use and must be injected without
delay. Avoid exposure to high temperatures and direct sunlight during inoculation. Keep
the remainder of the package at 4°C - BOC for use at least 3 weeks later.
DOSAGE: 2 ml subcutaneously
EFFECTS OF THE VACCINE
Animals inoculated for the first time may react slightly between the seventh and
fourteenth day following inoculation. During this period and for a further week these
animals should not be worked excessively. Immunity starts to develop two to three
weeks after complete inoculation and protection against some of the virus types are
achieved after four weeks. Immunity cannot be guaranteed in all animals.
PACKING
Available in series of 2 bottles sufficient for 1 dose.
Registration holder: Onderstepoort Biological Products (Ltd.), Private Bag XO?,
ONDERSTEPOORT 0110




VIRUS NEUTRALISATION TEST PROTOCOL
A5.1. Introduction
The virus neutralisation test is a quantitative assay for the determination of antibody titre
in, for example, serum, based on the ability of the serum to neutralise a known amount
of a standard virus antigen (Aleff Group, 2000). The African horse sickness virus
neutralisation test is a sero-specific test that measures the amount of IgG antibody
specific to each serotype in the serum.
Full procedural details of the method are given in Section A5.2 but, in summary, the
Biobest (2005) laboratory in the U.K. describes the test as follows: 'T he test uses
decreasing concentrations of the serum against a set amount of virus to check how
much neutralising antibody is present in the serum. Serial dilutions of the heat
inactivated serum are prepared in a 96 well plate and are incubated with a known
amount of virus (100TCIDso). Virus susceptible cells are added to the virus/serum mix.
After incubation, each well of the plate is examined for evidence of the viral cytopathic
effect (CPE), Le. how many of the cells have been killed by the virus. Sera containing
antibodies to the test virus are able to neutralise the virus and prevent infection of the
cells when they are added to the plate. Where the serum sample contains high
concentrations of antibodies, neutralisation of the antibodies will occur at even high
serum dilutions. Conversely , where the sample contains little or no antibodies, it is
unable to neutralise the virus even at the lowest dilution used in the test. The result of
the test is the point at which the serum sample has been diluted so that it is unable to .
neutralise all the virus in the test. This dilution is reported as the antibody titre of the test
sample."
Figure A5.1 is a diagrammatic representation of the test procedure. In this trial, the
results were measured in antibody titres doubling in strength from 1:2 to 1:4 to 1:8,
increasing to 1:256. The virology department at Onderstepoort Veterinary Institute
considers an antibody titre of 1:40 to be positive (Gerdes, 2004, pers. comm.). A
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Figure A5.1Diagrammatic representation of the virus neutralisation test (Biobest, 2005)
A5.2. Procedure
All work is conducted under Class 11 biohazard hoods and staff wear laboratory coats
and latex gloves. Sterile conditions are employed for all procedures
Step 1: Numbered plates16 are marked with sample numbers. Each sample is tested in
duplicate for each serotype and all the samples for one mare and her foal are tested
together (Le. at the same time) in a series of plates. See the example of Plate 1 in
Figure A5.2.
16 (NUNC , Microwell 96 well plate, flat bottom, AEC Amersham, item no. 167008)
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Figure A5.2: Example of plate layout and labelling (Plate 1)
Plates 2 and 3 are labelled as per Plate1, but with sample numbers from 1.6 to 1.11 and
1.12 to end, respectively. Any remaining columns on Plate 3 are used as cell control
wells (at least two columns) . Cell control wells (cells and medium only) are used to
check cell growth . A set of three plates as described are labelled for each of the nine
serotypes and numbered as below.
• Plates 1 - 3: AHS 1
• Plates 4 - 6: AHS 2
• Plates 7 - 9: AHS 3
• Plates 10 - 12: AHS 4
• Plates 13 - 15:AHS 5
• Plates 16 - 18: AHS 6
• Plates 19 - 21:AHS 7
• Plates 22 - 24: AHS 8
• Plates 25 - 27: AHS 9
Step 2: Twenty five (25) jJl of the cell growth medium is aliquoted into Rows B to H of
each plate. This medium consists of EMEM (Minimum Essential Medium Eagle) 17, with
a penicillin/ streptomycin/fungizone mix (PSF)18, non-essential amino acids (NEAA)19,
17 Bio-Whittaker, Cat. No. 12-136 F
18 Bio-Whittaker, Cat. No. 17-745 E
19 Bio-Whittaker, Cat. No. 13-114 E
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and L-glutamine20 mix added and supplies the necessary nutrients for the cell growth as
well as being the diluent for the serum.
Step 3: Fifty (50) IJI of undiluted serum (inactivated at 56°C for 30 min) is aliquoted into
Row A of each plate.
Step 4: Two-fold dilutions of each plate are made by mixing serum and medium . Twenty
five (25) IJI of serum is taken from Row A. This is mixed in Row B by evacuating and
refill ing the micro-pipette ten times. Twenty five (25) IJ I is taken from Row B and mixed in
Row C. This procedure is repeated to Row H, where the remaining 251J1 is discarded into
a biocidal solution.
Step 5: Twenty five (25) IJI of 1OOTCIDso virus is added to all wells except the cell
control wells (see Section A5.3 for description and calculation of 100TCIDso)
Step 6: Plates 28 and 29 are constructed as back titration plates (virus and vero cells
(see Step 9) only) . These are used to check when the plates are ready to be read.
Examples are shown in Figure A5.3. Dilutions are 10-fold from 100TCID so (see Figure
A5.3, Plate 28, AHS 1 for an example of the dilutions). 1OOTCIDsois the working dilution ,
see Section A5.3 for the calculation and explanation of the working dilution.
Step 7: All plates (1 to 29) are placed on a rocker (Stuart Scientific Platform Shaker STR
6) for 10 minutes to mix the virus and serum .
Step 8: All plates are then placed in an incubator (Forma Scientific Water Jacketed CO2
Inc, Model : 3164 SIN 36558/2762) for half an hour to an hour to allow the antibody-virus
binding to take place.
Step 9: Vero cell preparation:
The cells are grown in tissue culture flasks (roller, roux or 75 cm vero bottles")
containing EMEM with non-essential amino acids, L-glutamine and PSF.
a) Pour the medium out of the flask.
b) Rinse the flask with Hanks Balanced Salt Solut iorr" (HBSS) and place on the
rocker for 10 minutes.
c) Pour the Hanks solution out and replace with trypsin" to release the cells
from the surface of the flask .
20 Bio-Whittaker, Cat. No. 17-605 E
21 Adcock Ingram
22 with phenol red; Bio-Wh ittaker , Cat. No. 10-508 F
23 Bio-Wh ittaker
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d) Place on a rocker until all the cells are loose.
e) Pou r 500 ~I feta l calf serum" (FCS) into the flask to stop the action of the
trypsin .
f) Spray any left-over cells off the surface of the flask with a syringe and needle.
Pour into a 20 ml glass bottle and centrifuge for 10 minutes at 4°C to form a cell
pellet.
g) Pour off supernatant and replace with EMEM.
h) Disperse the cells with a syringe and needle.
i) Mix the cells with the required amounts of EMEM and FCS . (See calculations
in Section A5.3).
j) Use in the test wells or pour into a new f lask to grow again.
Plate 28
AHS 1 AHS2 AHS 3a
100TCID5o 10-
23 4+ 4+ 4+ 4+
10 x Oil 10::0·5 4+ 4+ 4+ 4+
10 x Oil 10-4.5 3+ + 2+ +
10 x Oil 10-5.5 Nothing
AHS4 AHS 5 AHS6
Plate 29
AHS 7 AHS 8 AHS 9
Cell Control Wells
a Degree of cytopathic effect (CPE) : + = 0 - 25 % CPE or 0 - 25 % cells dead
2+ = 25 - 50 % CPE
3+ = 50 - 75 % CPE
4+ = 75 - 100 % CPE .
Figure A5.3: Example of Plate 28 and 29, back titration plates, including dilution and
result examples.
24 Delta Bioproducts, Cat. No. 14-501AI
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Step 10: Add 100 1-11 cells to every well in each of the plates 1 - 29.
Step 11: Incubate the plates in the CO2 (5%) incubator at 3rC.
Day 1 and 2-
Day 3 onward -
Check the cell control wells: the cell growth should be fully
confluent (100% coverage) in the wells within 24 to 48 hours.
Check the back titrations on Plates 28 and 29: the plates are
checked by looking at each well under a microscope to determine
the degree of the CPE. The CPE is visible in the number of cells
that the virus has killed. The serotype is ready when the back
titration shows the pattern of CPE illustrated in Figure A5.3, Plate
28, AHS 3. When ready, fix all the plates for that serotype with
70% alcohol and stain plates with 1% basic fuchsin". When the
plates for the final serotype are ready, fix those plates and the
back titration plates.
The cells adhere to the base of the plate so when fixing the plates, the liquid is emptied
out, the plates are rinsed under gently running cold tap water and filled with 70% alcohol
for at least 1 minute. The alcohol is then emptied and then the plates are ready for
staining. Twenty five (25) 1-11 of basic fuchsin is aliquoted into each well by means of a
12-channel pipette, allowed to stand for at least one minute and then rinsed with tap
water and dried in the incubator. The living cells are stained pink by the basic fuchsin. If
there are no cells in the wells (destroyed due to CPE), the stain is washed away by the
water and the well appears clear.
Step 12: The plates are read either under a microscope or over a light box. The degree
of CPE is determined (as for the back titration plates) but on the basis of colour rather
than on the cells. As the living cells have been stained pink, if the well is pink then there
was no virus action (antibodies present). If there is no pink colouration then the cells
have all been killed by the virus. The CPE for each well is recorded into a table
representing the plate. The final antibody titre is taken as the dilution where there is less
than 25% CPE (Le. the first row where the reading is a "+" or no CPE present. An
antibody titre of 1:40 is regarded as positive and indicative of protection against clinical
infection (Gerdes, 2004, pers. comm.). Figure A5.4 shows an example of the final plate
and Figure A5.5 shows an example of the results for a plate.
25 Saarchem, made up as a 1% solution in 70% ethanol
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Figure A5.4 Example of virus neutralisation plate (own photograph)
Sample 12 12.1 12.2 12.3 12.4 12.5
Number
Dilution 1 2 3 4 5 6 7 8 9 10 11 12
1:2 - - 2+ + - - - - - - - - A
1:4 - - 4+ 4+ - - - - - - + + B
1:8 - - 4+ 4+ - - - - - 3+ + + C
1:16 - - 4+ 4+ - - + + + 2+ + 2+ D
1:32 3+ - 4+ 4+ - - 2+ - 4+ + 3+ 4+ E
1:64 + 4+ 4+ 4+ + + + 4+ 3+ 3+ 3+ F
1:128 - 4+ 4+ 4+ - - 4+ + 4+ 4+ 4+ 4+ G
1:256 - - 4+ 4+ 4+ 4+ 2+ + 4+ 3+ H
Result 1:16 <1:2 1:32 1:16 1:4 1:8
Figure A5.5: Example of results for a plate .
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A5.3. Calculations
TCIOso= tissue culture infective dose. Not all virus particles are infective and titration
methods only recognise infective particles . If a culture is inoculated with at least one
infectious unit (IU), it will be killed. There is, of course , a random distribution of infectious
particles in aliquots of a suspension. When this has been diluted to the point where, on
average, one half of the aliquots of 1 ml contain at least one infectious unit, then the
suspension is said to contain one TCIOso, (Reed & Muench, 1938).
The TCIOsotitre is determined by using virus titration. Four replications of titrations from
-1 to -7 are used. The plates are read after 7 days. An example of the final calculation
is 3 - ~ + 9/4 = 4.75 where :
3 is the highest dilution with 4 wells determined to be 4+wells
1 is the dilution difference and
9 is the number of wells with CPE (five plus the row of four used for
determining the highest dilution)
Working dilution or 100TCIOso=The logarithm of the TCIOso titre plus two equals the
logarithm dilution of the virus suspension containing 1OOTCI Oso.
For example, if TCI050 '= 10 -4.75 per 0.1 ml of suspension, then the log dilution of the
virus suspension containing 1OOTCl 0 50 in a volume of 0.1 ml = 10 -2.75.
The working dilution is 10 -2.7s.
Cell preparation: Each plate needs 11 ml (100 IJI / well) of the cells, EMEM and FCS mix.
Example: One roller bottle supplies enough cells for 60 plates, one roux
bottle supplies enough cells for 10 plates and one 75 cm vero
bottle enough cells for 3 plates.
60 plates * 11 ml = 660 ml
Use 700 ml as the final volume to allow for some spillage and
other losses . The final calculation of quantities if 8% FCS is
needed is therefore as follows: 56 ml FCS + 644 ml MEM.
Virus needed: 16 ml of virus solution is needed per serotype . The calculation to
determine the amount of virus and amount of EMEM in the final solution is as follows:
Working dilution =10 -2.6
A 10-
2
solution is made first by adding 40 IJI of virus to 3960 IJI EMEM (4
ml of 10 -2 solution results).
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To dilute this to a 10-2.6 solution, 1 part of the 10 -2 solution is added to 3
parts EMEM (from Table A5.1). The final mix is 4 ml of the 10 -2 solution
plus 12ml of EMEM to make 16 ml of 10-2.6 solution.
Table A5.1: Ratios for the preparation of virus dilutions
Dilution required Ratio (solution:EMEM) Parts (solution + EMEM)
0.1 1:1.2 1 + 0.2
0.2 1:1.6 1 + 0.6
0.3 1:2.0 1 + 1
0.4 1:2.5 1 + 1.5
0.5 1:3.2 1 + 2.2
0.6 1:4 1 + 3
0.7 1:5 1+4
0.8 1:6.3 1 + 5.3
0.9 1:8 1 + 7
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APPENDIX 6
VIRUS NEUTRALISATION RESULTS FOR NINE AHS SEROTYPES
The following tables show the virus neutralisation results for each of the nine African
horse sickness serotypes, with the first born (older) foals on the right hand side of each
table. Each column represents one foal, with the sequential samples running down the
column. The blue-coloured blocks indicate positive antibody titres and the yellow blocks
represent negative antibody titres (an antibody titre of less than 1:32). The white
squares show where no samples were taken. The rows labelled Vaccination 1 and
Vaccination 2 illustrate when the foals were vaccinated with the vaccine combination
containing the relevant serotype. The second vaccine combination would have been
three weeks later for Serotypes 1, 3 and 4, and three weeks earlier for Serotypes 2, 6, 7
and 8. Table A6.1 gives the birth dates of the foals.
The mares were all vaccinated on the 13 July 2000 and 3 August 2000 with AHS
vaccine combinations 1 and 2 respectively. The foals were all vaccinated on 1 February
2001 and 26 February 2001 with AHS vaccine combinations 1 and 2 respectively for the
first time. The foals were vaccinated again on 6 August 2001 and 28 August with AHS
vaccine combinations 1 and 2 respectively for the second time.



















































Table A6.2 Virus neutralisation results for AHS Serotype 1
+ + + Weak + Weak +
+ + + Weak + +
1 2 3 4 5
138 134 129 120 117
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Days: mare vac to foaling
~
vac 1 - 3.5 months
vac I - 3 months
vac 1 - 2.5 months
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Table A6.3 Virus neutralisation results for AHS Serotype 2
ZSTresult + + + Weak+ Weak+ + + + + + + + + + + + + + + - - + + Weak +
GC result + + + Weak + + + + + + + Weak + + + + + + + Weak + + +
Foal number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Days: mare vac to foaling 138 134 129 120 117 112 107 104 98 97 95 95 81 75 73 72 69 64 60 43 42 40 35 33
Foal age at vac 1 (days) 65 69 74 83 86 91 96 99 105 106 108 108 122 128 130 131 134 139 143 160 161 163 168 170
Mare 1:2 ' 1:256T 1:16 1:128 "~~~: 1:16 ;(F ' : 1:32,; 1:8" 1:16 ,( 1:16 ; 1:2 /; 1:8 / ) r: 1 28 ~ 1:64'i!: 1:2;( 1:256;' 1:32: 1 :32 ~ I:256;(;{;{i r:256 '~ I:2 ' 1:8 ' H 6,,; 1:16 1:8', '
Day 0 1:2' 1:2 1:2' ,1:2 ,(;' ; " 1:2" "1, 1:2" 1:2;' : 1:2"" 1':2 )2 1:2" 1:2 1:2:",; ; 1:2,;,1:/ 1:2;;:': 1:2('(;: 1':2< 1:2' :/ ; 1:2':(: ' 1:2 " 1:2 ) , 1:2 " 1:2,;\)" 1:2 ' 1:2 ",
Day 1 1:4'; 1:256: 1:8 1:2:';' ':;;]' 1:32;; 1:16 1:64'",,4 1:16 ' 1:16 :, 1:8 ; )/ ;, 1:128 ~ 1:256.1 1:32;1, 1: 64'ril 1:16
vac 1 - 5 montbs 1:2" ''''
vac I - 4.5 montbs 1:320/1,: 1:4 : 1:2 :, 1:2 , 1:2,:,
vac 1 - 4 months 1:64';;: 1:4;:: 1:2 ' 1:2 ",,'"
vac 1 - 3,5 montbs 1:16 1:16 1:2 } /,'\ 1:32 :'::;. 1:8" 1:4 ' " 1:2 / 1:2 ' 1:4 1:2
vac 1 - 3 montbs 1:64~ 1:16 1:8 ', " 1:2"/ 1:2 ',: 1:2/
vac 1-2.5 months 1:32 ;'jziil;~ 1:2 ,; ), jj: 1:2 ' 1:16 ' 1:2 1:2 : 1:2 ' ) " 1:8)/! 1:2 ',,' 1:2'; 1:2 " ' 1:2 ' 1:2 ",;; 1:2" 1:2'
vac 1 - 2 months 1:2 ' '. E128j; 1:4 1:2 "', 1:2 1:8 ' 1:2 ',' 1:4 , 1:2, 1:2 ' 1:2 " 1:2,. 1:2 ':
vac 1 -1.5 montbs 1:2 ' ( 256;; 1:4 , 1:322 1:2 ' 1:2,: 1:2 ' 1:2 ;)' ;;" 1:4', 1:4 "" 1:2 1:2 ! "': ,:j 1:2.:" ,·;' 1:2'.': 1:2"'" 1:2< 2/
vac 1 - I montb 1:2 1:2 ' 1:2 1:4 ;; 1:2 1:8 ,,;;; 1:2 : 1:2 ' 1:2' 1:2 ';;: ' 1:2 ,. 1:2 ; 1:2 '," 1:2' ,:; l:64 '~j 1:2 " 1:2 ; ,"': 1:2 ; 1:2' 1:2 ; '1:2' 1:2 / ;
vac 1- 0.5 months 1:128; 1:2 1:16 ' 1:4 1:2, ' 1:2; 1:2 ,)/ / ; 1:2 1:2 '
Vaccination 1 1:2 1:16 1:4 1:4 , · 1:2 ', \'] :8 ' 1:2 ; I:4 'i ..I:2 ' 1:2, 1:2 '" "" 1 :2 1:2 ' ' 1 :4' 1:4 ;. ' 1:2: ' 1:2 :; , <1:2 > ' 1:2; ' 1:2 ' 1:2 / 1:2': 1 :2,; ';';1:2;
vac 1 + 0.5 montbs
vac 1 + 1 montb 1:2' 1:2" 1:2,';: 1:2 ' 1:2,'/ ; 1:2 ' cl. ,· 1':64;1:;{ 1:2', i,:; 1:16 1:4" ':';, 1:8; 1:4, 1:2: ;;
vac I + 1.5 montbs 1:16 \,;; 1:2 , 1:2 " '" 1:2' :,;:; 1:4" " 1:16 1:2 : 1:2 " 1:4 ' 1:8" 1:2 >' ,
vac 1 + 2 montbs 1:2 1:2 ' ; 1:2 ,; 1:2 1:2"' 1:128; 1:4' 1:2 1:4 ' ; ; 1:32 :~i 1:2 ",; 1:16 1:8);" 1:256;;,[; 1:256';: 1:4 1:2 1:2 / :'
vac 1 +2.5 montbs 1:2 1:2 ' 1:2 1:16 1:32;,1 :8 -,
vac 1 + 3 montbs 1:2
vac 1 + 3.5 months 1:2 1:2 1:2 1:2 1:2 ", 1:2 1:2 "",1 :16 1:256'," 1:16 ' 1:256:; 1:2 1:8 1:256) 1:16 1:8 F64;9~:;';; 1':64]£,; 1:32: 1:16 1:2 ,,., , 1:8 , 1:2:,
vac 1 + 4 montbs 1:2
vac 1 + 4.5 months 1:2 1:2 1:2 1:2 1:2 , 1:2 1:2 ' 1:64'ii'; 1:256 ~ 1:64 ; 1:256! 1:2 " 1:4 1:2561' 1:2 , 1:256: 1:16 / ;; 1:16 ; 1:32; 1:8 1:128;, 1:2; 1:2
vac 1 + 5 months 1:2 1:2 ', l':128 :~, 1:128 1 :256,~ 1:2 1:16 : 1:2 1:2
vac 1 + 5.5 months 1:2 ' 1:2 :/" 1:2 1:2 ,: 1:2 " :"" 1:2 :, I:32 :~~ 1:4 : 1':64'~~ 1:2: ( 256; 1:8': 1:3i;: 1:4 ', ( :64:;i.'K
vac 1 + 6 months 1:2 1:2:'" 1:2 ; ;, 1:2 ' , 1:2,:. 1:2 ; f :32,;,g 1:4 ; 1:64:;:;; 1:16 ,,.," I:256 ;! 1:64'1'(;1 1:4: , 1:64~;{; 1 :2 ' , 1:32;;' 1:8:!5,,; 1:2 ", 1:4: 1:64 'j';~ 1:2 ( 1:2 '
vac 1 + 6.5 montbs 1:2
Vaccination 2 1:2 ,'; 1:2 '; 1:2 ". 1:2 ) ' .... ,.. .. ;::, 1:2 ;0, 1:2" l'f32 i1lfl l :4 1:64 .~ 1:16 .: , 1:256~ l :64y,*} 1:4 < f! 64!,'l' I :2';; 1:32\'0 1:3t)l~f~ 1:8 ' 1:2 1:4" 1:64~{i 1:2 .. 1:2 ' it
vac 2 + 0.5 montbs 1:2'""
vac 2 + I month 1:2 1:2 ' 1:32 iJr::ig~ 1:2:: :2'::: 1:4 ' 1:2 '.' 1:16 ' 1:16 L6d i&1:8 1:32 iff!;11:128"E32; li:32Jrv!i 1:8 1:64',~ 1:32!i1l':2i§'y 1:8 / . 1:4.. 1:2/2 1,32";(;/: I:2 1:2
vac 2 + 1.5montbs 1:2 , 1:2,'. 1:2 1:16 1:4' , 1:32;;;'1, 1':128'1 1:8 ' lA ; '
vac 2 + 2 montbs 1:8 1:2' ;·;"'J.'*iiilW' 1:2 ',/ ' 1:2 ' 1:32::1:' 1:8:04i'K\ 1:2 ;, 1':64/,\1) 1:8 ·'; ; 1:2 ';' 1:2' I:3Z2i1'; 1:2 " ,[ ,
vac 2 + 2.5 months 1:2
vac 2 + 3 montbs 1:16 1:2 1:2 ' ; 1:2 1:2 ' 1:8 ' 1:16 1:2 ' 1:8 ' ', 1:32:1,,;, 1:8 '/ 1 :32 ;~ I:128 ii, 1:8 ;·,' 11':32;;7/ 1:2 1:16 1:2 I:2 ;§i~f,;:'1,1
vac 2 + 3.5 months 1:32 ;:;; ." 1:32£'%' 1:8 1:4
...............
Table A6.4 Virus neutralisation results for AHS Serotype 3
ZST result + I Weak + + + + + + + + + + + + IWeak+
GC result + IWeak + Weak+ 1+ 1+ + + + + Weak+ 1+ 1+
Foal number 3 1 4 5 11 I 12 1 13 14 I 15 I 16 I 17 1 18 I 19 I 20 I 21 1 22 I 23 1 24
Days: mare vac to foaling 129 I 120 117 95 t 95 1 81 75 I 73 1 72 1 69 1 64 1 60 1 43 I 42 1 40 1 35 1 33
Foal age at vac 1 (days)
Mare
74 1 83 86 108 108 122
' 1:16 1:16 :U 28
Day 0
Day 1
vac 1 - 3.5 months
1:2 ' 1,1:21 ,1:2 :1 ,1:2':': 1 ' ,1:2 ' ,·1 "1:2 ' I' 1:2 ,1' '1:2 1' 1:2 ; 1 1:2 1:2 . 1: 1:2 <1 ' 1:2 "
1:41;1:256'1 1;;1:64 '
. 1:8 1 1:2 . 1:2
vac 1 - 3 months
vac 1 - 2.5 months L:3211:16 1;.1:2 >11:8 ;1 I 1<1:81 1:1 :2 . 11:2 11:4 " 1:2 1:2 ,
1:2 .
vac 1 - 2 months 1:2 '1:1:2561 11:8 :.1 I I J:16 1 I 11 :2 . 1:2 1:2
vac 1 - 1.5 months
vac 1 - 1 month
vac 1 - 0.5 months
1:161:2
'1:2 1:2 1,1 :2 :' 1. 1 :2 1': 1:2
1:2 1 1:4 I I
1:21 1:2" I 1:2
1:2 '1. 11:2
1:2 I : 1:2
1:2
1:2 ,
1:2 I 1 1:2 1 1:2 ' 1 1:2 1;' . 1:2
1:2 . 11:21:2 t 1:2 Ic1 :2
1:2 1 1:2 . 1 1:211 :2 1 1'1 :211:2 1 ,1:2









1:21 1:2 1 . 1:2
vac 1 + 1 month
vac 1 + 3.5 months
vac 1 + 0.5 months
vac 1 + 1.5 months
vac 1 + 3 months
vac 1 + 2.5 months
vac 1 + 2 months
Vaccination 1
1:2 I I 1:2 I 1:2
1:2 I 1:2 I 1:2 . I 1:2
1:211:2 '11:2 1 1:2





; 1:2 11 :2





1:2 1 1:2 I 1:2
1:2' 1 1:2 1 1:2
1:2
1:2


















vac I + 4 months
vac 1 + 4,5 months
vac 1 + 5 months
vac 1 + 6 months
vac 1 + 5,5 months
vac 1 + 6.5 months




1':25611:211 :2 1' 1:4 '
1:41 '1:25611:21 11 :2 1 11:2 ' 1:1:2: 1 1:2" IU6
1:4 '11:128 11:41 ' 1:2
1:2:
1:2 1 1:2 I · 1 :2 ' ,l i;1:32 ~1 01:4
.1:2 1 1:2
1.1:2 1 1:2
' 1:2 ';: 1:2 '
1:2 ,1' 1:2 1 1:2 ,1 " '1:2 ' I .: 1:2
1:2 11:2 I 1:2 I 1:2 ': 1 , 1:2
Vaccination 2
vac 2 + 1 month
vac 2 + 0.5 month
vac 2 + 1.5 months
vac 2 + 2 months
vac 2 + 2.5 months
vac 2 + 3 months
vac 2 + 3.5 months
vac 2 + 4 months
1:2 1 1:2 11:2 1:2 I I 1:2
1:21 1':1:32 ftl 1 . 1:2 t 1:21 1:2
1:21 ;1:64 ;1 1 1:2 1 11:1281 11:2 . 1 1:2
1:2 · lrH64 t1 1:16 I I I 1:2 I I ' 1:4 1 I 1:2 I 1 1:2 I ' 1:2
...........
N
Virus neutralisation results for AHS Serotype 4
+ + Weak + Weak + + + + + + + + + + +
+ + Weak + + + + + + + Weak + + + + +
2 3 4 5 6 7 8 9 10 11 12 13 14 15
134 129 120 117 112 107 104 98 97 95 95 81 75 73
69 74 83 86 91 96 99 105 106 108 108 122 128 130
~, (.'~j 'l 'lr' f i17,R J!ii f;~2'1i1;; ",1)'(;'4'; T"~1i 1':1&' 1)/':1:"
Foal number I 1
GC result 1 +
Days: mare vac to foaling 1138
11:4
+ + + + - - + + Weak +
+ + Weak + + +
16 17 18 19 20 21 22 23 24
72 69 64 60 43 42 40 35 33
131 134 139 143 160 161 163 168 170
' 1:16 "





<1 ' ~' 1'ri"o "' I:;r:~ : 1~H: g
,1:8
I ,,",
I ' ,· 1"' ; 1 1:2
65
C32 lu 2Day 1
vac 1 - 3.5 months
vac 1 - 3 months
vac 1 - 2.5 months




ZST result I +
vac 1 - 2 months
vac 1 - 1.5 months 1:21 1:2 '
1:161 11:161 1:16 '
1:4I il :64'll:2! /1:8
d :4', 1:2 '
·1:4, 1 1:2 11:2, 1:2 '
12 12





vac 1 + 1.5 months
Vaccination 1
vac 1 + 0.5 months
vac 1 + I month
vac 1 - 1 month
vac 1 - 0.5 months
·1:4 11 :2
vac 1 + 2 months
vac 1 + 2,5 months
vac 1+ 3 months
vac 1 + 3.5 months
1:21~
1:2 I I 1:2
1:2
1:2 1:4 '11 :4
1:2
1:2 1' 1:2" I 1:2
;"1'; 1'\
1:2
1:2 1:2 11:2 1:2
1:21 1 :1 :2
1:2 11:2 1 11:2
1:2
1 :2· I, 1:2 .;
1:2 1 1:2 ,"










1:8 1 1:8 11:2
1:21 I 1:2 I 1:4 1 1:2 11:2
1:2 11:2 ' 11:2 I
I 1:2 1 1:2 I 1:2 I 1 1:2










' 1:2 ,I 1:2





vac I + 6.5 months
vac 1 + 5.5 months
vac 1 + 6 months
vac 1 + 4 months
vac 1 + 4.5 months
vac 1 + 5 months
Vaccination 2
vac 2 + 0.5 month
vac 2 + I month
vac 2 + 1.5 months
vac 2 + 2 months




1:2 11; 1 1 '8
>'0 I , ... " " 1:4\ ' 1',1:2 .,
', 1:8
vac 2 + 3 months
vac 2 + 3.5 months
vac 2 + 4 months
1:2 11:2 11 :21 1 1:2 I 1:4
""';1:32';;d 1 1:2 I 1 1:2 11:2 1 1:2 I , 1:2 1:2 1:2 1 1 1:8';
11:8 I 1:4 '























18 I 19 1 20 1 21
64 I 60 1 43 I 42
139 1 143 1 160 I 161
Weak +1 +
1 1:4 ' I 1:4
. 1:2
+ I + I +
+ I + I +
+
+
14 I 15 I 16 1 17
75 1 73 1 72 I 69
128
1:16
1:2 ' 1 1:16
11:1281
" :2
1:2 1 1:2', 1:2
+ + + + + +
+ + + Weak + + +
8 9 10 11 12 13
104 98 97 95 95 81




1:2 11:8 1 11:2 :, 1-"1:2
+ I + IWeak + 1 + I + I +
+ I + IWeak + IWeak +1 + I +
21314 5 16 17
134 I 129 I 120 I 117 I 112 1 107
65
1:2
1:4 ' 1:16 • 1:2
1:4
Davs : mare vac to foaling 1138
ZST result I +







Foal number 1 1








052 ,1 l::l I 1:16 11:16 1 1"1:32'
1:256 ' I :'64;
, . 1:8
1:2 1 1:2
1:2 I 1:2 1 1:2
1:2 . " 1:2 1:2 ' 1:2 ·
' 1:2
1:2 1:2 . 1:2 '




1:2 1 I J :2 1 1:2 ·






1:8 1 1:2 I 1:2 I 1:2 1 1:2
1:2 I 1:4
1:8
f: 256 1· 1:2
1:2
1:128






















. 1:8 i c! l :2
1 1:2 1:2 I 1:2 I 1:4






1:2 I 1:2 1 1:2 .
1:21 1:2 I,1:2


























Table A6.7 Virus neutralisation results for AHS Serotype 6
ZST result + + + Weak+ Weak+ + + + + + + + + + + + + + + - - + + Weak+
GC result + + + Weak + + + + + + + Weak + + + + + + + Weak + + +
Foal number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Davs: mare vac to foaling 138 134 129 120 117 112 107 104 98 97 95 95 81 75 73 72 69 64 60 43 42 40 35 33
Foal age at vac I (days) 65 69 74 83 86 91 96 99 105 106 108 108 122 128 130 131 134 139 143 160 161 163 168 170
Mare 1:64 m56 i" 1 :64j<A :J 28~ ')1:128\1j l :256 1:256 1:256 1:256 '1 :16 .i1:256t' 1:256 1:256 '11:64 1:256 1:128 1:256 jA: 1 28 ~ r:J28 1:256 1:256 1:256 1:256 ;·I :128i
Day 0 1:2i §I!'1:41)' ",] :2;'1 :2" '1' 1:2'\ '! J';1 :2'ii/.1:2{i'H:2" \01:2'( ;;;,1:2'';: "j1!H:2,KW\ ,1:2' ,,'1:2}'" 'i1 :2!'( 1:2"' H :2W\ 1:21!I Hi!i il:2!!C '\\ 1:2 ,i;'1 :2X i,1 :2Yi 1:1" 1:2"< i';; H:2 ""
Day I 1:32 1:256 1:128Id ':256 ii' I :2 I:256 1:256 1:128 1:256 J'256 lm28i,; 1:256 1:2.56 I:256 1:256
vac I ·5 months 'ij: 128
vac I - 4.5 months 1:256 ~r:32i ' 1 :8 )'):32 :; 1:8
vacl-4months k if " , ( 128 1:128 ii!1':128!i '~, 1 : 32
vac 1-3,5 months E256 1 :16 ' 1:4 ',1:32, 1:256 1:64 1:32 ""; 1:16+' "1:16; 1:2
vac I - 3 months I :256 ~I :32 I :256 1:32<' "1 :8 ;, 1:2,
vac 1- 2.5 months ,1:32 1:2" 1:128 1:256 1:256 1:8., 0;1:16 1:4 1:16 1:256 1:16 1:4 1:2 1:2 1:2
vac I - 2 months 1:32 IJ:32 1:256 1:2 H ::52J f1':64* 1:4 I :64' I :32 I:16 ;;1:2 ' 1:2 1:4
vac 1-1.5 months 1:16 '''1:64:1 1:16 1:128 1:16 1'&1"1i4 1 'R 1:2 1:2 1:8 1:2 1:8 1:2i I:2 1:2 1:2
vac I-I month 1:16 t:'1:32~'lJ : 3 2",1 1:256 "1':32'1 1:161:161:4 , 1:2 1:4 1:4 1:2 1'32 ' 1:8 1:8 1:4 1:8 1:2 , 1:2 1:2 ' 1:2 1:2
vac 1-0.5 months 1':64' 1:8 1:2 ;;1:8 ' il :32, 1:4 ' 1:161:2, 1:2
Vaccination 1 fi64 1':256 1:8 1:2 1:2 1:16 1:8 ,1:82' 1:t6 i,'1:2 '. 1:4 · ' 1 :2 1':8 1:2 1':16 1:16\ !1 :4 1:2 1:4 1:2 1:2 ' 1:2 1:2 1:2
vac I + 0,5 months
vac I + I month 1:2 1:8 1:4 iJ :8 1:2 1:4 1:2 1:2 1:2 1:2 1:2; 1:2 1:2
vac I + 1.5months 1:16 1:2 1:2 1:2 1:8 1:32 1:2 1:4 ' 1:2 ' 1:4 1:2 '
vac 1+2 months 1:2 1:8 1:4 1:2 1:2 1:8 1:2 1:2 1:2 1:2 1:2 1:2 1:4 1:2 1:8 1:2 1:2 1:2
vac I + 2.5 months 1:16 1:2 1:16 1:8 1:4 1:2
vac I + 3 months 1:2'",
vac I + 3,5 months 1:2 1:4 1:2 1:2 1:2 1:4 1:2 1:2 1:2 1:2 1:2 1:2 1:2 1:32 1:32 1:4 1:2 1:8 1:2 " 1:2 1:2 1:2 1:2
vac 1+4 months 1:4
vac I + 4,5 months 1:2 1:8 1:2 1:2 1:2 1:2 1:2 1:4 1:2 1:2 1:2 1:2 1:2 1:16 1:4 1:16 1:4 1:2 1:4 1:2 1:2 1:2 1:2
vac I + 5 months 1:2 ,1:2 I :2 I :2 I :2 I :2 I :4 I :4 I :2
vac I +5.5 months 1:21 :32 1:4 1:2 1:2 1:2 .,1:8 1:2 1:64,;. 1:4 1:4 1:4 1:16 1:2 1:2
vac I + 6 months 1:2 1:2 1:2 1:2 1:8 .,;1:2 ,;1: 8;ilW:64~ 1:2 1:2 1:21 :128 1:21:64" 1:16" ' 1:2 1:4 1:2 ' 1:4 1:16 ' ) :2' p l :8 ', 1:8
vac I + 6.5 months 1:8
Vaccination 2 '1:2 1:2 ",1 :8 '" : 1 :2 1:2 1:8 '" 1:2 " 1:8! ,,1:64'; '11 :2" 1:2 " 1:2 1':128 1:2 1:64., '1:16 1:2 ' 1:4 " ;'1:2";"'1:4 1:16 1:2"1 1:8 iI, I :8
vac 2 + 0.5 months 1:4
vac 2 + I month 1:4 1:8 1:8 1:4 1:8 1:2 JI :64i,H :32I P1:2 1:4 ,1:4 1:256 1:4 1:8 1:256 4 :32': 1:8 '~1:64i 1:2 il:32; 1:4 ;' 1:2 1:8
vac 2 + 1.5months 1:2 1:8 1, 1:8'; ;'1 :2 1:4 1:2 ;,1:64 1:2 1:2
vac2 + 2months 1:41 :16 1:8 1:2 1:2 '1:32' 1:2 1:16 1 :128 ~1 :32 H:32" ;, 1:4 1:16 1:2 1:4
vac 2 + 2.5 months 1:4
vac 2 + 3 months 1:4 1:8 1:2 1:2 1:2 1:4 1:2 1:4 1:4 1:64';, 1:2 1:16 1:128 1:2 1:8 J :16 1:2 1:2 1:8
vac 2 +3,5 months 1:16 1:8 1:128 1:4
..........
CJ'I
Table A6.8 Virus neutralisation results for AHS Serotype 7
ZST result + + + Weak + Weak + + + + + + + + + + + + + + + - - + + Weak +
GC result + + + Weak + + + + + + + Weak + + + + + + + Weak + + +
Foal number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Davs: mare vac to foaling 138 134 129 120 117 112 107 104 98 97 95 95 81 75 73 72 69 64 60 43 42 40 35 33
Foal age at vac I (days) 65 69 74 83 86 91 96 99 105 106 108 108 122 128 130 131 134 139 143 160 161 163 168 170
Mare 1:32 1': 128 IGI28 ¥W2561Lli l : 1 28 ,~ ~J:3 2' 1:256 1:256 J.i:t28 ~t:32' ~!tI 28 ' 1:256 1:256 1:32 1:128 1:128~ 1:128 1:32 C256 1:256 1:64 :~H:64'~'
Day 0 1:2 1:2W 1:2 "J :2 1:2 ,,1:2 "'1:2 '1:2"" ;,i1:2'!: >1:2 ; 1:2 ',':1:2 1:2 1:2 :;:{ :2," ':1:2,', , 1:2 1:4 1:2 1:2', ::1:2" 1:2 1:2 1:2
Day I 1:8 1:128 1:16 1:16 1:128 1:64, 1:256 1:128 1:256 1:64< 1:32 1:256 1:2 1:128
vac I - 5 months 1:16
vac I - 4.5 months 1:256 1:4 1:8 1:8 1:2
vac I - 4 months 1:128 '1:2 "':,1:8 ,," 1:2 ,',
vac I - 3.5 months 'I\J21 " 1:8' 1:8 '; '1 :4 ": %1:32: 1:16 1:128 '1:8 " '!I :8 . 1:2
vac I - 3 months CU 8 1:32' 1:16 1:8 1 :2, 1:4
vac I - 2.5 months 1;llit,f:321\' 1:2 1:8 1:8 '1:32" 1:8 1:8 1:4 1:2 1:2 1:2 1:8 1:2 1:2 1:2
vac 1-2 months 1 :8 ;1 :32:, r:64~ 1:2 1:2 1:16 1:2, 1:4 1:2 1:2 1:2 ' 1:2 1:4
vac I - 1.5 months 1:2 I : 8 " \\'; 1:3t:~;, J :32 1:2 I:16 , 1:2 1:8 1:4 1:8 I:2 1:2 1:2 1:2 1:2 1:2
vac I -I month 1:4 "1":64'; , 1:4 , 1:16 1:2 1:16 "1:4 ' 1:4 1:2 1:2 1:4 1:2 1:4 1:2 1:2 1:2 1:2 1:2 :1:2 1:2 1:2 1:2
vac 1- 0.5 months 1:16 1 :16 t' I :256'i 'I :4;:; 1:4'" 1:2 1:21:2 /'1:2
Vaccination 1 1:2 1:8 1:81:2 1:2 1:16 1:2 1:21:2 '1:2 1:2 1:2 1:2 1:2 1:2 1:2 1:4 1:2 1:2 1:2 1:2 1:2 1:2 1:2
vac 1 + 0.5 months
vac I + I month I :2 I:2 I :2 .1:2 1:2 1:2 1:2 I:2 I:2 I:2 I :2 1:2 1:2
vac I + 1.5 months 1:2 1:4 1:2 1:2 1:2 1:2 1:2 1:2 1:2 1:2 1:2
vac 1 + 2 months I :2 1:2 ;.'1 :2 1:2 I :2 I :2 1:2 1:2 I :2 I :2 1:2 1:2 1:2 1:2 1:4 1:2 1:2 1:2
vac 1 + 2.5 months 1:2' 1:2 1:2 1:2 1:2 1:2
vac 1 + 3 months 1:2
vac I + 3.5 months I:2 I:2 I :2, 1:2 1:2 I :2 I :2 I :2 I :2 I :2 I:2 I :2 1:2 1:2 I :2 I :2 1:2 1:2 I :2 1:2 1:2 1:2 1:2
vac I + 4 months 1:2
vac 1 +4.5 months 1:21:21:4 1:2 1:2 1:21:21:2 1:2 1:2 1:21 :2 1:21:21:21:8 1:2 1:21:21:21:21:2 1:2
vac 1 + 5 months 1:2 1:2 1:2 1:2 1:2 I :2 1:2 1:2 1:2
vac 1 + 5.5 months 1:2 1:2 ,1:2 ':1:28 1:2 1:2 ,' 1:2 1:2, :1:2" '1 :2 ""1:2 1:2 1:2 ':1:2 ,/1:2
vac 1 + 6 months 1:2 1:2" ':';11':2 , '1 :2 , 1:2 1:2 Ll :2" / 1:2' 1 :2 ' 1:4 1:16 1:16 ,1:8" H128 1:16 "'1:2 ' 1:8 1:2 ' "1:2' ,:1 1:2'/1 " 1:4 1:2 lA
vac 1 + 6.5 months 1:2',
Vaccination 2 1:2 1:2 1:2 ,,1:2 1:2 ' 1:2 1:2 1:2 1:2 1:2 1:4 1:16 1:16 1:8 1:128 1:16 1:2 1:8 1:2 1:2 1:2 1:4 1:2 1:4
vac 2 + 0.5 months 1:2
vac 2 + I month 1:2 1:2 1:2 1:2 1:128 1:2 1:2,': ;,1 :2 1:2 1:2 1:128 1:128 1:8':; 1:256 1:2 , 1:2 1:4 1:128 ,1:2 1:4 " 1:2 1:2 1:2
vac 2 + 1.5months 1:2 1:128 ' 1:2 ', ;!l:2 1:2 , 1:128 1:128 !! 1:4 ", 1:2
vac 2 + 2 months 1:2 1:2 1:2 1:2 1:2 1:2 1:8 ;l':Mi 1:2 1:2 1:128 1:2 1:2 1:4 1:2
vac 2 + 2.5 months 1:2
vac2 + 3 months 1:2 1:2 1:2 .1:32 1:2 1:2 1:2 1:2 1:64 1:1281 :16 11:64" 1:2 1:4 1:32' 1:2 1:4 1:2 1:2
vac 2 + 3.5 months 1:2 1:2 1:2 1:2 ......
......
CJ)
Table A6.9 Virus neutralisation results for AHS Serotype 8
ZSTresult + + + Weak + Weak + + + + + + + + + + + + + + + - - + + Weak +
GC result + + + Weak + + + + + + + Weak + + + + + + + Weak + + +
Foal number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Davs: mare vac to foaling 138 134 129 120 117 112 107 104 98 97 95 95 81 75 73 72 69 64 60 43 42 40 35 33
Foal age at vac I (days) 65 69 74 83 86 91 96 99 105 106 108 108 122 128 130 131 134 139 143 160 161 163 168 170
Mare 1:32 0 2 U2 I: 128 I :256 1:64. 1:256 I': 18'1' 1:256 1:256 J :256 li256 1:256 1:256 ::"1:256,, 1:256 1':04 1:256 J :256 1:64 ii}J :256
Day 0 H:2< "1:2 ' 1:2 i;:;Fl :200' '1 ' 1:2'" 1:2::Mi 1:2' ,d :2:;: :1 :2' T1:2 ' I:2,! <:1:2 ,) '{1 :20'1\01:2',; 'HI:2'> '1 1:2!':" "1:2 , ;1:2., 1):1:2;' / 1:2 ·; 1:2 ' 1:2
Day I 1:'32 1:64 1:3218'(;128,;; 1:32 1:128 1:128 1:64 'd". 1:256 1:128 1:256 1:256
vac I - 5 months I :2
vac 1 -4.5 months 1:256 1:16 1:2 H:32 1:4
vac I - 4 months I :64; cl :64:: (in :64 " 1:4
vacl-3.5months 1:16 liU S ,;J :16 ' 1:256 mf:32H I:16 H:32\ "'1,J :32!; 1:256 4:2
vac I - 3 months 1:32 11:32.i ~JT32! :1:32" '1 :4:1 :2;:
vac 1 - 2.5 months 1:4 ' 1:16 ,1 :32,, :.t l l :8 1:256 i:H':64'; '5,J :87 ":,'1:32)/ 1:128 1:2 ' 1:2 1:2
vac I - 2 months I :16 1:32 1:64 1:4 1:32 "1:32" iI :32 f!:320 : 1:4 I :16 1:2 1:2 1:4
vac 1 -1.5 months 1:4 1:16 i{H:64;S' 1:8 01:32 1:4 1:16 1:4 1:32 1:8 1:8 jil :32 1:8 1:2 1:2 1:2
vac I-I month 1:4 1 :4 1f!\r:32,~i 1:2 1:8 1:16 1:2 1:8 1:2 1:16 1:8 1:8 :fJ :32\ d :2 1:16 1:2 1:8 1:2 1:2' 1:2 1:2 1:2
vac 1-0.5 months 1:8 1:4 ,f1:256i! 1:8 1:16 1:2 1:81:2 1;1:2
Vaccination 1 1:2 1:4 1:4 ! 1:8 ' 1:2 1:2 1:83 ' 1:4 1:2 '1:8 ' 1:2 1:8 1:2 1:8 ' 1:4 '1:4 "H4 1:2 1:8 1:2 1:2:: ':,1:2 ;, ',1 :2 >1:2
vac I + 0,5 months
vac I + I month 1:2 1:2 1:2 1:2 / 1:2 , 1:2 1:4 1:2 1:16 1:2 1:2 1:2 1:2
vac 1+ 1.5 months 1:2 1:2 1:8 " 1:2 1:2 1:8" 1:2 1:2 1:2 1:21:2
vac I + 2 months 1:2 1:2 1:2 1:2 1:2 1:2 1:2 1:4c; 1:2 1:2 1:2 1:32 1:2 1:8 1:8 1:2 1:2 1:2
vac I + 2.5 months I :2 ,TI:128 ' 1:4 1:4 1:2 1 :2
vac I + 3 months 1:2'
vac I +3 .5 months 1:2 1:2, 1:2 "1:2 ' ::1:256'"' 1:2 1:2 1:21:2 1:2 1:4 1:2 1:8 1:16 1:2 1:4 1:2 ' 1:2 1:41:2 1:2 1:2 1:2
vac I + 4 months 1:2
vac I + 4.5 months 1:2 1:2 1:2 1:2 1£1 :256< 1:2 1:2 1:2 1:2 1:2 1:2 1:2 1:2 1:8 1:2 1:4 1:2 1:2 1:2 1:2" 1:2 1:2 1:2
vac I + 5 months 1:2 1:2 1:2 1:2 I :2 I :2 I :2 I :2 1:2
vac I + 5.5 months 1:2 1:2 1:2 I :2 tH :256 1:2 1:2 1:4 1:2 1:2 1:2 1:2 1:2 1:2 1:2
vac I + 6 months 1:2 1:21:2 ') iJrI :256 I :2 1:2 1:2 1:2 1:2 1:2 1:8 I:128 '1:8 1:8 : Wf 32, 1:2 :1:2 1:2 1:4 1:4 1:2 1:4 1:2
vac I + 6,5 months >1:2
Vaccination 2 1:2' 1:2 1f21:2 h 1256 1:2 1:21:2 1:2, 1:2 1:2 1:8 1:128 1:8 1:8 ;; t,I :32; "1:2 1:2 1:2 1:4 1:4 1 ;;1:2 1:4 1:2
vac 2 + 0.5 months 1:2
vac 2 + I month 1:2 1:4 1 :2 ~1 :256 1:2 1:4 1:8 1:2 1:4 1:8 1:4 1:128 1:256 1:8- 1:16 1:2 1:4 1') 2, 1:16 1:16 1:2 1:4 1:2
vac 2 + 1.5 months ,1:2 1:2 1:2 lid :2 ,, '1:2 1:4 I :64 1:4 1:2
vac2 +2months 1:8 1:4 :1:2 7-I:128 " 1:2 1:32) d :641: H:4 :)1:8 1:4 1:16,' 1:16 1:8 "1:2 >' 1:2
vac 2 + 2.5 months 1:2
vac2 + 3 months 1:21 :32 l ' ( 64: 1:2 1:2 1:2 1:2 1:2 1:4 li64 1:64 1:2 1:16 1:2 1:16 1:8 1:2 1:2 1:2
vac 2 + 3.5 months 1:2 I :32' 1:8 1:8
..........
-...l
Table A6.10 Virus neutralisation results for AHS Serotype 9 (note: Serotype 9 not included in AHS vaccination)
ZSTresult + + + Weak + Weak + + + + + + + + + + + + + + + - - + + Weak +
GC result + + + Weak + + + + + + + Weak + + + + + + + Weak + + +
Foal Dumber 1 2 3 4 5 6 7 8 9 10 II 12 13 14 15 16 17 18 19 20 21 22 23 24
Days:marevactofoaling 138 134 129 120 117 112 107 104 98 97 95 95 81 75 73 72 69 64 60 43 42 40 35 33
Foal age at vac I (days) 65 69 74 83 86 91 96 99 105 106 108 108 122 128 130 131 134 139 143 160 161 163 168 170
Mare 1:4\1 :64, 1:16 J, I : 256'i' H :256'~ 1:256 1:256 1:256 1:256'1:16 ~f: 1 28~ 1:256 1:128 1:128 1:256 1:256 1:256 '1,1:2561; 1:256 1:25(f 1;256,1 :256 1':64 ~l': 1 28
DayOJ:2; ' 1:2" 1:2 I;;, 1:2 ii' "1:2 "11:2 ';4 :20,1'1:2;: iH:2:f '01:2 'i ',{4 1:2";,,", '1:2 ,,1 :2 11:2 ;;:1 :2" ' 1:2'" 1:2"( ," 1:2 "1:2'fl :2];I'*I:2:', i! :2 1:2 1:2
Day I 1:16 1:256 1:16 ~1 : 1 2 8::,i r:128 1:256 1:256 1:128 1:256 ~n28:~ 1:256 1:256 1:256 1:128
I month 1:4 1:64\' 1:32 1:64 ~ 1:2 1:256 n :64Hl:~4 ! :;\1:16 1:128 1:128 1:8 1':256
1.5 months ,1:4 >1 :32 1:2 1 :16 1~256 1:256 '1'32 1:64' 1:128 / 1:8 1:4 1:128 1:8
2 months 1:2 1:2 1:64 '\!, ~1 :32, 1:256 'li1:32, 1:4 1:16 ;:1:32 1:256 ,1:32",;.1 :64"'", 1:256 1:4
2.5 months l:32t 1:2 1:16 1:128 1:16 1:2 1:8 1:2
3 months 1:2 1:4 1:4 DI :128, 1:32 1:8 1':256 '1:16'1:8 .: 1':2 1:16 1:4 1:128 1:8 1:16 1:16 n 28 , 1:8 1:2 1:2
3.5 months 1:8 1:2 '1 :32; ,1:16. ' 1:4 1:2 1:8 1:8 1:2 1:8
4 months 1:2 1:8 1:16 :H:32'i 1:8, 1:2 1:128 ,):41:8 1:8 nU8 ' 1 :8' 1:2 1:4 1:2 1:2
4.5 months 1:2 1:21:21:2 i 1: 2 "" " 1:4 ·1:64, "1 :2'1:8 1:2 1 ~1:32i ' 1:2{
5 months 1:2 1:2 1:2 1:2 1:16 1:4 " 1:2 1:2 1:16 '1:2 1:4 '1:2 ,,1 ','1:2'/; 11:4 1:2 1:2
5.5 months 1:2 J:4 1:8 1:21:2 1:2 1:4 1:4 1:16 1/1:2 1" 1:2 (, 1:2 1:2
6 months 1:4 1:4 1:2 1:16 1:2 1:8 '1:2 1:2 1:2
6.5 months 1:2 1:2 1:2 1:8,; ' 1:2, ,1:2 1:4 1:16 1:2 1:2 1:8 1:16 1:2 1:2
7 months 1:2 1:16 1:2 1:32 1:8
7.5 months 1:2 1:2 1:2 1:4 1:2 1:4 1:8 1:2 1:16 1:16' #.1 :32 , 1:8/ 1:2 1:2 1:2 1:2
8 months 1:2 1:16 ' f M:' 1:4 1:128 1:8
8.5 months 1:2 1:2 1:2 1:2 1:2 '.1:64' 1:4 1:2 1:8 1:128 1:8 1:8 1:8 1:2 1:2 1:2
9 months 1:2 1:2 1:2 1:4 1:2 jl :32" 1:8 il :64 1:16 1:16
9.5 months 1:2 1:2 1:4 1:2 1:16 1:2 ,1 :4 1:16· ;,1:32 1:2 1:4 1:128 1:2 1:64' ,1:321' 1:2 1:2
10 months 1:4 1:2 1:2 1:2 1:2 1:16 1:2 :8 :f 1:2 ,1:4 1:2
10.5months 1:8 1:81:8, ',:1:8, ; ,,1 :16" ~r:64" 1:2 ' 1:128 .(21 :2 ,.1:"64' tid ' lIig Hl il "Fi "J :8
II months 1:16 "1:2 1:2 1:4') ,1:2,' 1:16 1:8 ", ~ 1: 32 1:256 '''!I :8:! ',1:64,' !:!'1 :4$: 1:4 1:2
11.5months "1:64'1!i: 1:4 114".1:4\ ,1:8 , 1:8 " 1il :64~ '@ 1:128Xi "1':2 i .1 M l:W ''! :2' ,,1 :2
12 months 1:4 1:2 1:2 1:2 H':321 1:4 :fl :24:8 ' "1':64', 1:256 n :32 1:256 1:8, 1':128 '1:16 ;:1:4 1:8'
12.5 months 1:8 1:256 (\1:128;- 1:256 1:64 1:4
13 months 1:64'" 1:2 1:2 1:128 Pl :64 ' 1:4 1:256 "·d :64~;\ 1:4 '1 :16 lA '
13.5months 1:4 1:8 1:2 1:2 1:4 '~ 1 : 64~ i"'i 1:32 1:8
14 months ,1:64 "1:32 1:128 .1:32 1:41:16 1:8 1:32
14.5 months 1:32) 1:8 :;1:32:; 1:4
15 months 1:2 1:4
15.5 months 1:2 1:16 1:2
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